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1. Introduction 
Lysosomal storage disorders comprise a group of more 
than 30 different diseases. The common feature of these 
diseases is the deficiency of a lysosomal protein that is 
part of a catabolic pathway. The deficient proteins may be 
hydrolases or cofactors involved in the degradation of 
macromolecules or transporters, which deliver catabolic 
products to the cytosol. Most of lysosomal enzymes are 
exohydrolases acting in sequence, such that substrates are 
degraded by a stepwise removal of terminal residues. 
Thus, the deficiency of a single enzyme causes the block- 
age of the entire pathway, since the failure to remove a 
terminal residue makes the substrate inaccessible for fur- 
ther hydrolysis by other lysosomal enzymes. The lysoso- 
mal storage diseases can be classified depending on the 
pathway affected and the nature of the accumulated sub- 
strate. Ten different deficiencies can affect he degradation 
of mucopolysaccharides (mucopolysaccharidoses), five de- 
fects are known in the degradation pathways of glyco- 
proteins, one for the intralysosomal storage of glycogen 
(glycogenesis) and eight deficiencies affect sphingolipid 
catabolism (lipidoses). However, there are frequent over- 
laps of storage material between those groups. Many lyso- 
somal hydrolases are not specific for a particular com- 
pound, but rather for a terminal residue, which may be 
identical in, e.g., gangliosides and glycoproteins, o that 
both compounds accumulate when a commonly required 
enzyme is deficient. So far, no lysosomal storage disorders 
of nucleic acid or protein degradation have been described. 
The synthesis and intracellular sorting of lysosomal 
enzymes have been reviewed in detail recently [1,2]. Solu- 
ble lysosomal enzymes follow a common intracellular 
route. A signal peptide mediates the cotranslational trans- 
port across the membrane into the lumen of the endoplas- 
mic reticulum (ER). In the lumen of the ER, the signal 
peptide is cleaved and the polypeptides cotranslationally 
receive N-linked oligosaccharide side chains. Subse- 
quently, lysosomal enzymes are transported to the Golgi 
apparatus where they are recognized by a phosphotrans- 
ferase. This enzyme transfers N-acetylglucosamine 
(GlcNAc)-l-phosphate from UDP-GIcNAc to mannose 
residues of oligosaccharide side chains of lysosomal en- 
zymes generating GlcNAc-l-phospho-6-mannose residues. 
In a second step, GlcNAc is removed by a N-acetylglu- 
cosamine- 1-phosphodiester-ot-N-acetylglucosaminidase 
leaving behind a mannose-6-phosphate residue. This 
residue binds to mannose-6-phosphate receptors, which 
mediate the further vesicular transport to the lysosomes. 
Two receptors of different molecular weight - 46 kDa and 
300 kDa - are known, which have different binding 
properties and intracellular distribution [166]. Enzymes 
bind to receptors in a late Golgi compartment and dissoci- 
ate upon acidification i  a prelysosomal compartment. The 
enzymes are delivered to the lysosomes while receptors 
recycle. After arrival in the lysosome, most lysosomal 
enzymes undergo a limited proteolysis, which finally yields 
the mature enzymes. Although mannose-6-phosphate re- 
ceptors play a major role in the intracellular t ansport of 
newly synthesized enzymes in fibroblasts, additional pro- 
teins may be required for targeting to lysosomes in other 
cell types. Thus, trafficking of lysosomal enzymes in 
hepatocytes, Kupffer cells and leucocytes i not severely 
impaired by a deficient phosphotransferase ctivity [325]. 
However, in many cells the critical step for the correct 
sorting of lysosomal enzymes is the recognition by the 
phosphotransferase. Since there are no apparent similarities 
among lysosomal enzymes it is still unknown what struc- 
ture common to all lysosomal enzymes is recognized by 
this enzyme. The recognition domain is part of the protein 
backbone of the lysosomal enzymes and depends on their 
proper three dimensional folding [21]. In the lysosomal 
aspartylprotease cathepsin D two discontinuous sequences, 
each of which contributes to the phosphotransferase recog- 
nition domain, have been identified [3,4,305,306]. Other 
lysosomal enzymes like /3-o-galactocerebrosidase and /3- 
o-glucocerebrosidase r , though they are no transmem- 
brane polypeptides, membrane associated and sorted inde- 
pendently of the mannose-6-phosphate receptor pathway 
[5], but details of their transport have not yet been eluci- 
dated. A third group are the transmembrane lysosomal 
proteins for which the classical ysosomal marker acid 
phosphatase is the best known example. This enzyme is 
synthesized as a transmembrane precursor and sequences 
in the cytoplasmic tail have been shown to be necessary 
and sufficient for lysosomal targeting [6]. In the lysosome 
the luminal domain is proteolyticaUy cleaved to yield the 
mature soluble acid phosphatase. Other lysosomal mem- 
brane proteins like LIMP and LAMP follow similar intra- 
cellular outes [7], but are not converted into soluble forms 
in the lysosome. Diseases due to mutations in these type of 
proteins have not been described and their function is not 
clearly understood. 
Almost all lysosomal storage diseases show clinical 
variability. Most diseases vary with respect o the age at 
onset and progression of the symptoms. The later a disease 
begins the more protracted is the development of symp- 
toms. Frequently, three different ypes of disease are dis- 
tinguished, severe infantile, intermediate juvenile and mild 
adult forms, respectively. Although such a classification is
u ful, it should be realized that the spectrum of clinical 
severity is a continuum, and such imposed istinctions are 
artificial. In many lysosomal disorders ymptoms in the 
early and late onset forms are similar, but in some diseases 
defects in the same gene may cause very different pheno- 
types. For example,/3-o-galactosidase eficiency can cause 
either GM1 gangliosidosis and Morquio type B disease. 
Whereas in GM1 gangliosidosis neurologic degeneration is 
the major symptom, patients with Morquio Type B disease 
have no neurologic involvement, but severe skeletal dys- 
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plasias. Similarly, in Gaucher disease depending on the 
involvement of the nervous ystem neuronopathic and non 
neuronopathic forms are distinguished. 
During the last years much effort has been devoted to 
the cloning of genes of lysosomal enzymes and to the 
analysis of mutations [8]. A large amount of data has 
accumulated, sothat this review will focus on the molecu- 
lar biology of lysosomal storage diseases. 
In the first part, I will review some of the molecular 
genetic data for each disease separately, whereas data on 
the pathogenesis and therapy of lysosomal storage diseases 
will be discussed in context in the second part. Since not 
all mutations can be reviewed in detail, I will focus on 
those which are frequent, important for the understanding 
of genotype-phenotype correlation or reveal some interest- 
ing biological aspect of the defective nzyme. The figures 
try to give condensed information about he gene structure 
and the mutations of most of the genes. References in the 
figures should allow convenient access to the original 
literature. Figures are only included for genes for which at 
least four different mutations have been described. Other- 
wise mutations are mentioned in the text. The frequencies 
of some alleles are indicated in the figures. It should be 
noted that these numbers may only have a limited validity, 
since in many cases they represent the results of only one 
study and may only be valid for certain ethnic groups. 
Some diseases will not be discussed, since no progress has 
been made in the cloning of the respective genes or 
elucidation of the genetic defect. These involve diseases 
caused by defects in lysosomal transporters, which have 
been covered by a recent review in this series (see Pisoni 
et al. [79]). 
2. Lipidoses 
2.1. GM2 gangliosidoses 
This group of diseases is characterized by storage of 
G~a 2 ganglioside [138]. Three polypeptide chains encoded 
by three different genes are involved in the degradation of
GM2 ganglioside. The synthesis of an a and fl-subunit for 
fl-hexosaminidase (/3-N-acetyl-D-hexosaminidase) llows 
for the formation of three isoenzymes trot, aft, and tiff, 
which are designated fl-hexosaminidase S, A, and B, 
respectively [138]. The fl-hexosaminidase isoenzyme A 
removes terminal N-acetylgalactosamine from GM2 gan- 
glioside [314]. In order to be hydrolysed by fl-hexosa- 
minidase A, the ganglioside has to be associated with a 
third polypeptide, the GM2 activator protein, which solubi- 
lizes the substrate for the action of the enzyme [312,314]. 
The storage of GM2 ganglioside can therefore be due to 
mutations in three different genes: (1) The fl-hexosamini- 
dase a-subunit gene, which causes classical Tay Sachs 
disease or late onset GM2 gangliosidosis (variant B); (2) in 
the /3-subunit gene, which causes early or late onset 
Sandhoff disease (variant 0); and (3) the GM2 activator 
protein (variant AB) [138]. 
These variant forms of disease are clinically similar, but 
differ in the composition of compounds which besides GM2 
ganglioside are also found in the storage material. The 
presence of additional compounds i due to the fact that 
GM2 ganglioside is not the only substrate of fl-hexosa- 
minidase A, and that the isoenzymes differ in their sub- 
strate specificities and dependence on the presence of the 
G m activator protein. The substrate specificities of the 
isoenzymes have either been demonstrated directly or have 
been concluded from the compounds found in the storage 
material. Generally, fl-hexosaminidases release terminal 
/3-glycosidically linked N-acetylgalactosamine or N- 
acetylglucosamine from a variety of substrates, fl- 
hexosaminidase A cleaves phingolipids such as GM2 gan- 
glioside [314], GDlaGalNAc [312], GA2 glycolipid [314] 
and globoside [314] as well as oligosaccharides [315,316]. 
In contrast fl-hexosaminidase B does not hydrolyse G m 
ganglioside [312] nor GDlaGalNAc and cleaves GA2 gly- 
colipid only inefficiently [314]. Isoenzyme S has limited 
catalytic activity and is rapidly degraded [387]. Absence of 
isoenzyme A in variant B thus causes storage of GM2 
ganglioside [313], GDlaGalNAc [312] and to lower extent 
of GA2 glycolipid [313], while oligosaccharides and globo- 
side are hydrolysed by the unaffected isoenzyme B [317]. 
In variant O both isoenzymes A and B are deficient, so 
that besides Gra 2 ganglioside and GDlaGalNAc, globoside 
[314] and oligosaccharides [308] are stored and the amount 
of glycolipid GA2 is increased several fold compared to 
variant B [314]. Most of these compounds are stored in 
neurons, oligosaccharides are stored in viscera and brain 
and globoside is only found in the viscera [308,314]. In the 
variant AB only those compounds accumulate, which hy- 
drolysis depends on the presence of the activator protein, 
such as GM2 ganglioside and GA2 glycolipid [314]. 
GDlaGalNAc and oligosaccharides are, in contrast to Tay 
Sachs and Sandhoff disease, not stored in the GM2 activa- 
tor protein deficiencies. It has been shown in vitro, that 
hydrolysis of these compounds is activator protein-inde- 
pendent, which explains the lack of storage in the activator 
protein deficiencies [60]. Since all variant forms of disease 
are similar, the symptoms eem to be mainly due to the 
storage of G m ganglioside and not that of other com- 
pounds. 
Tay Sachs disease and GM2 gangliosidosis 
Classical Tay Sachs disease is characterized bya rapidly 
progressing neurological degeneration. The disease starts 
in between 3 to 5 months of age with progressive weak- 
ness and hyperirritability. A macular cherry red spot is 
seen in all patients. Progression of neurologic symptoms 
leads to the decerebrate, vegetative state in the second to 
fourth year of life [138]. In the juvenile form the onset of 
disease is later and the progression is slower. Adult GM2 
gangliosidosis represents he mildest form of the disease, 
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which starts in 2nd to 3rd decade of life and presents with 
neurologic symptoms of spinocerebellar nd lower mOtor 
neuron origin, like ataxias, dysarthrias and muscle weak- 
ness. Psychiatric symptoms are frequently present. A par- 
ticular variant, which has been termed chronic, starts in 
between the age of 2 and 5, but patients urvive well into 
adulthood [138]. 
Tay Sachs disease is most prevalent in the Ashkenazi 
Jewish population. Three defective /3-hexosaminidase a- 
subunit alleles account for 93% of all mutant alleles in this 
ethnic group [9]. One allele shows a 4 bp insertion in exon 
11 [10], the second has a splice donor site mutation in 
intron 12 [11-13] and the third, which causes milder Gu2 
gangliosidosis, is characterized by a Gly-269 > Ser substi- 
tution in exon 7 [14,15] (see Fig. 1). The insertion of 4 bp 
in exon 11, as well as the intron 12 splice site mutation 
result in a severe reduction of/3-hexosaminidase a-subunit 
mRNA and protein. The 4 bp insertion in exon 11 does not 
interfere with the processing of the primary nuclear mRNA 
transcript, but produces a frameshifl with premature termi- 
nation 9 nucleotides downstream. Thus, this mRNA should 
be translated into a truncated polypeptide. However, the 
insertion causes instability of the mRNA demonstrating 
that the machinery of the cell is able to recognize a 
nonfunctional mRNA at or prior to the level of translation, 
the underlying mechanism of which has yet to be eluci- 
dated. Not all transcript with premature t rmination codons 
are unstable, but similar phenomena have also been re- 
ported, e.g., for /3-hexosaminidase fl-subunit [300], fl-D- 
glucuronidase [213] and a-L-iduronidase transcripts with 
premature termination codons [254]. 
The Gly-269 > Set substituted a-subunit causes a re- 
duction of the amount of functional heterodimeric enzyme, 
which is due to a decreased stability of the mutant a-sub- 
unit [282]. The enzymatic deficiency is, however, not 
complete, since the mutant a subunit still yields a low 
amount of functional heterodimeric /3-hexosaminidase A 
[16]. The genotype phenotype correlation in /3-hexosa- 
minidase a-subunit deficiencies can be explained by the 
complete loss of functional enzyme in case of the 4 bp 
insertion in exon 11 and the intron 12 splice donor site 
mutation and the low amounts of residual activity associ- 
ated with the Gly-269 > Set allele. Homozygosity for ei- 
ther of the first two alleles causes the severe classical Tay 
Sachs disease, whereas patients with adult GM2 gangliosi- 
dosis have been found to be genetic ompounds for one of 
these alleles and the Gly-269 > Set allele [17]. One copy 
of the Gly-269 > Set allele is sufficient o confer the mild 
1 kb 
I"----4 
(27) Del 7,6 kb 
I 
/ I 
3/3 
I 
¢q 
11/0 16/73 eClS 
AAA A 
Fig. 1. Structure of the fl-hexosaminidase a-subunit gene and mutations causing Tay Sachs disease and G m gangliosidosis. The figure shows the structure 
of the fl-hexosaminidase A a-subunit gene. Boxes indicate exons, lines introns hatched parts 5' or 3' untranslated sequences. Mutations are indicated and 
the numbers in parenthesis give the references [10,11,14,18-20,22-24,26,27,31-33,35-46,246] in which the mutations have been described. Numbers at 
the bottom depict the exons in which the mutations occur. Mutations which are associated with a juvenile or aduR phenotype are shown on the top, those 
which cause an early onset severe phenotype or which phenotype association could not be determined are shown on the bottom. B 1 mutations are depicted 
by italic letters and lines point to the location in the gene. Bold letters how pseudodeficiency alleles and the bold lines indicate the most frequent mutant 
alleles. Numbers give the frequencies (%) in the non Jewish/Jewish community, respectively. As far as alleles with mutations other than amino acid 
substitutions are concerned, the splice site mutations are indicated whether they occur in an exon (Ex) or intmn (Int), the number of the exon or intron in 
which they occur and whether they represent splice donor (SD) or splice acceptor (SA) site mutations. In case of small deletions (Del) the deleted bases are 
indicated and the following number either designates the codon in which this deletion has been found or the cDNA position of the deletion, depending on 
the designation i the original paper. 
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adult phenotype and the few patients identified being 
homozygous for this allele seem to have a more protracted, 
milder course of disease than those, who are genetic 
compounds [17]. 
The correlation of residual enzyme activity and severity 
of the clinical phenotype in /3.-hexosaminidase a-subunit 
deficiencies has also been demonstrated biochemically 
[234]. Cultured fibroblasts of patients with various clinical 
forms of disease were fed with the natural substrate GM2 
ganglioside and the degradation rate was determined. Pa- 
tients with milder forms of disease had a higher turn over 
rate than those with severe forms. In the range of low 
residual enzyme activities GM2 ganglioside degradation 
increased steeply with slight increases of residual enzyme 
activity and it is estimated that about 10-15% of residual 
enzyme activity is sufficient o sustain a normal phenotype 
[234]. 
With one exception [246] the Gly-269 > Ser allele is so 
far the only allele that has been found in adult GM/ 
gangliosidosis patients. Most of the remaining defective 
alleles cause classical Tay Sachs disease and only three 
have so far been characterized, which lead to the juvenile 
intermediate ype of disease. These alleles encode an a- 
subunit with an Arg-504 > His [18], an Arg-499 > His [18] 
and a Gly-250 > Asp substitution [19], respectively. The 
Arg-504 > His and the Gly-250 > Asp substituted a-sub- 
units are misfolded and retained in the ER [18,283]. In 
fibroblasts of a patient with the Gly-250 > Asp substituted 
a subunit enzyme activities higher than those found in 
fibroblasts of infantile Tay Sachs patients have been 
demonstrated, when measured with an artificial substrate 
[283]. It is likely that low amounts of the mutant a-sub- 
units are able to leave the ER and provide lysosomes with 
low residual enzyme activity, producing the juvenile phe- 
notype of the patient. 
Two other mutations affect codon 504, a deletion of 
Cytosine 1510 [20] and a Arg-504 > Cys substitution [22]. 
Introduction of the latter mutation into the normal /3- 
hexosaminidase cDNA and expression studies revealed 
that the effect of the mutation was similar to that of the 
Arg-504 > His substitution. However, although the same 
codon was substituted and data from expression studies 
were similar both alleles are associated with different 
forms of disease, juvenile GM2 gangliosidosis (Arg-504 > 
His) and classical Tay Sachs disease (Arg-504 > Cys), 
respectively [23]. 
The frequency of the exon 11 4 bp insertion, intron 12 
splice donor site mutation and the Gly-269 > Ser allele has 
been determined in Askhenazi and non Jewish populations. 
The 4 bp insertion allele represented 73% of mutant alleles 
among Ashkenazi Jews, the intron 12 splice site mutation 
15%, and the Gly-269 > Ser allele 3%. In the non Jewish 
population the exon 11 4 bp insertion allele accounted for 
only 16% of defective alleles, the intron 12 splice site 
mutation could not be detected and the frequency of the 
Gly-269 > Ser allele was identical to that found in Ashke- 
nazi Jews [9]. Examination of defective alleles among non 
Jews revealed a donor splice site mutation in intron 9, 
which has a frequency of 11% and is thus the second most 
frequent allele among non Jews [25]. However, Tay Sachs 
disease among non Jews is far more heterogeneous than in 
the Ashkenazi population [26,246]. 
Two other ethnic groups, both descendants from French 
settlers, have a high incidence of Tay Sachs disease. One 
is the Cajun community in southwest Louisiana, in whom 
the 4 bp insertion in exon 11 was found in 11 of 12 mutant 
alleles examined [24]. The other group are the French 
Canadians in which a 7.6 kb deletion in the 5' region of 
the gene, which has occurred by illegitimate recombination 
between Alu repeats, accounts for more than 80% of 
defective alleles [27,28]. 
A particular form of /3-hexosaminidase A deficiency is 
the so called B1 variant, which is characterized by an 
altered substrate specificity of the enzyme. It displays 
normal activity towards non sulfated artificial substrates 
used in the diagnosis of Tay Sachs disease, but fails to 
degrade GM2 ganglioside, the natural substrate [29,30]. 
Five different mutations have been found in B1 patients. 
Three affect the same codon, causing the substitution of 
Arg-178 by His [31], by Cys [32] or Leu [33]. The Arg-178 
> His allele, which has also been called DN allele, seems 
to be the most frequent B1 allele. This allele is found 
panethnicaUy, but with a particular high frequency in 
northern Portugal [34]. Although this mutation might have 
evolved independently in various parts of the world, it 
seems likely that its panethnic occurrence is at least in part 
due to Portuguese colonization. Two B1 mutations have 
been found in different codons, one is a Va1-192 > Leu 
[35] and the other a Asp-258 > His substitution [36]. The 
region of the a-subunit involved in the recognition of GM2 
ganglioside is obviously larger, as was assumed on the 
basis of the initially identified Arg-178 > His mutation. As 
far as the genotype phenotype correlation is concerned, a 
genetic ompound for a null allele and a B1 allele suffers 
from infantile Tay Sachs disease, whereas homozygosity 
for the Arg-178 > His allele was found in 10 juvenile 
patients [34]. 
Two other interesting mutations affecting substrate 
specificity are localized in the region in which the B1 
mutations occur. Enzymes bearing an Arg-247 > Trp [37] 
or an Arg-249 > Trp substitution [38] have reduced activ- 
ity towards an artificial substrate. However, for the Arg- 
247 > Trp substitution ormal activity towards the natural 
GM2 ganglioside has been demonstrated [37,307]. Since 
the diagnosis and heterozygote detection is mostly based 
on enzymatic assays with artificial substrates a healthy 
individual may appear /3-hexosaminidase A deficient in 
this assay. Likewise, in genetic counselling an individual 
heterozygous for this allele may be considered as a Tay 
Sachs disease carrier. Similar phenomena have also been 
described for other lysosomal enzymes [386]. Enzyme 
deficiencies, which do not cause disease, have been termed 
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pseudodeficiencies. Pseudodeficiencies are without clinical 
consequences for the carriers, but cause problems in the 
diagnosis and genetic counselling. 
When Jewish and non Jewish suspected Tay-Sachs 
disease allele carriers, which were identified by enzyme 
activity determinations, were examined for the presence of 
these pseudodeficiency alleles, the Arg-247 > Trp and the 
Arg-249 > Trp allele was found in about 40% and 6% of 
non Jewish individuals, respectively [37,38,310]. The Arg- 
249 > Trp allele was not found among Jewish suspected 
carriers [38], while conflicting data have been presented 
about the frequency - -  3% to 30%-  of the Arg-247 > Trp 
allele in this ethnic group [37,310,311]. 
Sandhoff disease 
Since the fl-subunit is part of two different /3-hexosa- 
minidase isoenzymes, its deficiency causes the loss of 
isoenzymes A and B. Deficiencies of the /3-subunit have 
been termed Sandhoff disease [47]. The clinical phenotype 
and heterogeneity is similar to that found in a-subunit 
deficiencies. The cDNA [229] and the gene of the /3-sub- 
unit of fl-hexosaminidase have been cloned [55,156] The 
disease is rare, but there are some demographic isolates 
with a high frequency, e.g. in a region around the town of 
Cordoba in Argentina [48]. The most frequent defect found 
in the fl chain gene is a 16 kb deletion that removes the 
promoter and exons 1 to 5 (see Fig. 2). This deletion 
accounts for 27% of Sandhoff alleles and most likely arose 
from a recombinational event between two Alu repeats. 
Homozygosity of the allele causes the severe late infantile 
form of the disease [49]. 
As in Tay Sachs disease the milder forms have been 
found to be associated with mutations leading to the 
synthesis of enzymes displaying some residual activity 
[285]. In many of lysosomal storage diseases mutants, 
which result in residual enzyme activity, express amino 
acid substitutions, that cause a substantial, but incomplete 
loss of enzyme activity. Sandhoff disease provides an 
example in which splice site mutations are still associated 
with some residual enzyme activity, because the normal 
splice site is still used, although at much lower frequency 
[50]. Nucleotide sequences at and near the splice site 
ensure the precision and effectiveness of intron removal. 
Mutations in these nucleotide sequences may affect splic- 
ing in a way that the effectiveness of splicing at the correct 
site is reduced, leaving most of the transcripts aberrantly 
spliced, while only a few transcripts will still be spliced 
correctly. These mutations cause a reduction, but not a 
complete deficiency of functional mRNA and therefore a 
reduced synthesis of a structurally unaltered enzyme. In 
the fl-hexosaminidase fl-subunit gene one of these muta- 
tions is not found within the splice acceptor consensus 
sequence, but in the coding region of exon 11, 8 nu- 
cleotides 3' of the splice acceptor site. It changes an amino 
acid (Pro-417 > Leu), but this substitution is benign, since 
it does not affect the function of the enzyme. This muta- 
tion, however, influences the use of the preceding splice 
acceptor site. Analysis of the fl-subunit mRNA revealed 
that in most, but not all transcripts exon 11 was skipped 
due to selection of a splice donor site further downstream 
[50]. The patient in whom this allele was found had the 
juvenile form of the disease and was homozygous for this 
allele. 
A 57 year old patient with a very mild adult type 
Sandhoff disease was identified, who was a genetic com- 
pound for the frequent 16 kb deletion and the exon 11 
splice site selection mutation [51]. Four of his fl-hexosa- 
minidase deficient siblings were still healthy at an ad- 
vanced age (55 to 61 years of age). Compared to the 
homozygous juvenile patient mentioned above, there is an 
apparent discrepancy in the genotype phenotype correla- 
tion, the molecular basis of which is unknown. These cases 
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Fig. 2. Structure of the /3-hexosaminidase fl-subunit gene and mutations causing Sandhoff disease. The designation fmutations i  as described in Fig. 1, 
with references in parenthesis [48-50,52-54,284,285,300]. In this figure, the exon location of mutations i  not given by numbers but the lines point o the 
location. Bold line depicts the most frequent allele. Number gives the frequency of the allele among patients. Bold letters depict a pseudodeficiency allele, 
which has also been termed Hexosaminidase Paris. Mutations causing late onset disease are shown on top, others at the bottom. 
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demonstrate hat other factors can influence the outcome 
of the disease substantially. Both patients came from a 
different ethnic background, the juvenile patient being 
Japanese and the adult patient French Canadian. One can 
speculate that genetically determined ifferences in the 
splicing machinery might cause a more efficient selection 
of the normal splice site and thus lead to a higher residual 
enzyme activity in the French Canadian family. Late onset 
forms of disease, which are caused by similar splicing 
defects, have also been described in galactosialidosis [89] 
and Scheie type MPS I [256,266] (see respective para- 
graphs). 
Two other mutations, which cause the generation of 
new splice sites, have been described: a G > A transition 
in intron 12 creates a new splice acceptor site [52,53] and 
leads to the insertion of 24 additional nucleotides, and a 
duplication including the splice acceptor site at the junc- 
tion of intron 13 and exon 14 is the cause of an 18 nt 
insertion [53]. Since both insertions are in frame, an elon- 
gated /3 chain is synthesized. In both cases the mutant 
polypeptides are unstable and they do not reach the lyso- 
some, since they are degraded in an early biosynthetic 
compartment [53]. The intron 12 splice site allele was 
found in a juvenile Sandhoff patient, who was a genetic 
compound with a null allele [52]. It is assumed that the 
normal splice site might still be used at low frequency in 
this patient and that the transcripts are translated into 
functional enzyme. An asymptomatic but /3-hexosamini- 
dase deficient father and sibling of a juvenile Sandhoff 
patient was found to be a genetic ompound for the intron 
12 splice site allele and the duplication allele of the intron 
13/  exon 14 junction [53]. The latter allele was initially 
termed /3-hexosaminidase Paris [309]. In spite of the dupli- 
cation, low levels of normally spliced transcript were 
detectable in the cells of this individual [53]. The low 
amount of normal mRNA may supply the cell with suffi- 
cient enzyme to prevent the development of disease, which 
means that this allele by definition is a pseudodeficiency 
allele. Since the a-subunit is still produced in normal 
amounts, the low amounts of/3-subunit will predominantly 
form a//3 /3-hexosaminidase A heterodimers. Only very 
little fl//3 homodimer will be allowed to form. Since the 
carrier of this allele is healthy, it means that in vivo very 
low amounts of the fl-hexosaminidase B isoenzyme are 
sufficient o maintain a normal phenotype or the deficiency 
may be compensated for otherwise. 
Four mutations causing premature termination codons 
in the /3-subunit mRNA have been examined in more 
detail [300]. Three of these lead to an about 100-fold 
decrease in mRNA steady state level and one to a 3-fold 
decrease. The latter 3-fold reduced mRNA and one of the 
severely diminished species have stop codons at adjacent 
amino acid positions 451 and 454. So far there is no 
explanation why premature termination codons occurring 
at about the same position within a mRNA can have such 
different effects on steady state mRNA levels. 
The effects of the I1e-207 > Val and Tyr-456 > Ser 
substitution on the /3-hexosaminidase /3-subunit have been 
studied, because a patient with a peculiar clinical and 
biochemical phenotype was a genetic compound of these 
alleles. The symptoms in this adult patient started at the 
age of seven years with muscular weakness and a slowly 
progressing lower motor neuron disease [284]. Thus, the 
patient can be classified to suffer from chronic GM2 gan- 
gliosidosis. In the fibroblasts of this patient no /3-hexosa- 
minidase B (/3//3) polypeptides or catalytic activity could 
be detected. Surprisingly, about 30% to 50% of normal 
amounts of fl-hexosaminidase A (a / /3 )  protein and activ- 
ity was found when measured with an artificial substrate 
[385]. It was demonstrated that the I1e-207 > Val substi- 
tuted fl-subunit does not self associate to form /3//3 
homodimers. Monomers are rapidly degraded explaining 
the lack of /3-hexosaminidase B. However, the mutant 
/3-subunit dimerizes with the a-subunit to form stable 
/3-hexosaminidase A heterodimers. The presence of the 
hexosaminidase A could explain the mild phenotype of the 
patient [385]. 
G M 2 activator protein deficiencies 
The third polypeptide involved in the degradation of 
GM2 ganglioside is the GM2 activator protein. The defi- 
ciency of this protein is rare and causes a disease that is 
clinically similar to Tay Sachs disease. This small 24 kDa 
protein interacts with the a-subunit of the fl-hexosamini- 
dase isoenzyme A [317] and solubilizes lipids such as GM2 
ganglioside or GA2 glycolipid for the hydrolysis by /3- 
hexosaminidase A [314]. The cDNA and gene of this 
protein have recently been cloned [56]. Two mutations 
have been described so far. One is a Cys-138 > Arg 
[57,58] and the other an Arg-169 > Pro substitution [59]. 
2.2. GMZ gangliosidosis and morquio type B disease 
Deficiency of the enzyme /3-D-galactosidase can cause 
very different clinical phenotypes, fl-o-galactosidase hy- 
drolyses fl-glycosidically inked terminal galactose residues 
from a variety of different substrates. These substrates are 
lipids such as GM1 ganglioside [318], oligosaccharides 
with terminal galactose [319,326] or galactose containing 
intermediates of the degradation of the mucopolysaccha- 
ride keratan sulfate [319,327]. A complete deficiency of 
the enzyme results in the storage of all substrates 
[319,326,327]. Accordingly, GMI gangliosidosis presents 
clinically with neurologic symptoms, which can be at- 
tributed to the storage of GM1 ganglioside in neurons, 
while storage of keratan sulfate catabolic intermediates in 
the viscera results in hepatosplenomegaly andsevere bone 
deformities typical for mucopolysaccharidoses. GM1 gan- 
gliosidosis may appear as a severe rapidly progressing 
infantile disease in which the neurologic symptoms domi- 
nate the clinical picture, but skeletal deformities, edema, 
hepatomegaly and coarse facial features are also present 
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[319]. The adult form of GM1 gangliosidosis shows mild, 
slowly progressing neurologic involvement like dysarthrias 
or gait disturbances and, except for vertebral dysplasias, 
little involvement of the skeleton [319]. Since GM~ gan- 
glioside metabolism seems to be normal in Morquio type 
B disease [377], patients have no neurologic involvement, 
but demonstrate progressive skeletal dysplasias. Intermedi- 
ate phenotypes between these clinical extremes also exist 
and it has therefore been suggested that the term /3- 
galactosidoses describes diseases due to the deficiency of 
/3-D-galactosidase more comprehensively [321]. 
The fl-D-galactosidase cDNA [61] and the gene [62] has 
been cloned and a variety of mutations have been charac- 
terized (see Fig. 3). Defective alleles are heterogeneous 
and no single mutation with a particular high frequency 
has been found. So far 20 amino acid substitutions [63-65], 
two duplications of 23 nt [66] and 165 nt [64] and three 
splice donor site mutations [276,279,320] have been de- 
scribed in GM1 gangliosidosis patients. As in other lysoso- 
mal storage diseases, homozygosity for a null allele (e.g., 
the 165 nt duplication) was found in patients with the 
severe infantile form of the disease [64]. Juvenile patients 
were found to be genetic compounds or homozygous for 
an allele with an amino acid substitution (Arg-201 > Cys). 
Expression of a cDNA carrying this mutation in trans- 
formed h~man fibroblasts howed some residual enzyme 
activity, when measured with an artificial substrate [64]. 
The Arg-201 > Cys substituted enzyme does not associate 
with the protective protein, which is thought o stabilize 
/3-D-galactosidase in vivo (see paragraph on galactosialido- 
sis), and is therefore rapidly degraded [322]. 
Although the disease is genetically heterogeneous 
[63,64] one allele prevails among patients with adult GM1 
gangliosidosis. When 16 Japanese patients were examined, 
13 were homozygous for an allele carrying an Ile-51 > Thr 
substitution [64,67]. One patient was a genetic ompound 
for this allele and an Arg-457 > Gin substitution, and the 
remaining two were homozygous for the latter. The Ile-51 
> Thr allele showed residual enzyme activity towards 
artificial substrates in transfection studies with mutated 
cDNAs and in the patients fibroblasts [64]. Only a small 
amount of the Ile-51 > Thr substituted enzyme is trans- 
ported properly to the lysosomes and expresses ome 
enzyme activity. For the majority of the mutant enzyme 
transport seems to be disturbed at or prior to the Golgi 
apparatus [322]. Although all patients homozygous for the 
Ile-51 > Thr allele suffered from late onset GM1 gangliosi- 
dosis, there was still a remarkable heterogeneity in the 
clinical phenotype, demonstrating once more that there are 
other factors influencing the phenotypic expression of 
lysosomal disease [67]. 
In Morquio type B disease three different mutant alleles 
found in two patients have been detected, characterized by 
a Trp-273 > Leu, Arg-482 > His and Trp-509 > Lys sub- 
stitution [65]. Both patients were genetic compounds for 
the Trp-273 > Leu allele and one of the two other alleles, 
respectively. In the same study, these alleles were not 
found among patients with GM1 gangliosidosis, uggesting 
that these alleles were specific for Morquio Type B dis- 
eases. An Italian Gra 1 gangliosidosis patient was identi- 
fied, who was homozygous for the Arg-482 > His allele 
[68]. Thus, only the Trp-273 > Leu allele can therefore be 
considered specific for Morquio type B disease. This muta- 
tion may affect he substrate specificity of the enzyme in a 
way that affinity or hydrolysis for keratan sulfate is de- 
creased, but normal for GM1 ganglioside [299,377]. This 
may solely lead to the storage of keratan sulfate, but would 
not affect GM1 ganglioside metabolism. The Trp-273 > Leu 
substituted enzyme is normally processed, transported to 
the lysosome and stabilized by the protective protein [322]. 
It has a reduced specific enzyme activity towards an 
artificial substrate [322], but its substrate specificity has 
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Fig. 3. Structure of the fl-D-galactosidase gene and mutations causing GM1 gangliosidosis or Morquio type B disease. Labelling of mutations is as 
described before, with references in parenthesis [63-67,276-279,320]. The bold letters depict amutation causing Morquio type B disease. / /  indicates 
that he intron size is not known. 
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not yet been analysed in detail. Theoretically, heterozygos- 
ity for a GM1 gangliosidosis and a Morquio type B allele 
should result in Morquio type B syndrome, since the 
normal catalytic activity of the Morquio allele towards 
GM1 ganglioside should compensate the defective GM1 
gangliosidosis allele. 
2.3. Galactosialidosis 
This disease is characterized by the combined defi- 
ciency of two enzymes fl-D-galactosidase and N-acetyl-a- 
neuraminidase [319,328]. This is caused by the deficiency 
of a 'protective protein' [379], which associates with these 
two enzymes and forms a high molecular weight (> 600 
kDa) complex [87]. Complex formation leads to the stabi- 
lization of fl-D-galactosidase [82,332] and the activation of 
neuraminidase [83,331,332]. Neuraminidase hydrolyses 
a-glycosidically inked neuraminic acid from oligosaccha- 
rides and glycolipids [334]. Oligosaccharides with terminal 
neuraminic acid are therefore one of the major stored 
compounds in galactosialidosis patients [335,336], but 
oligosaccharides terminating with galactose have also been 
detected [336]. In tissues of the nervous ystem avariety of 
lipids containing neuraminic acid and galactose has been 
found in the storage material (e.g. GM1, GM2, GM 3 gan- 
gliosides) [337]. 
Patients with the infantile form of disease suffer from 
edema, ascites, skeletal deformities visceromegaly and 
variable involvement of the nervous system [333]. The 
phenotype ranges from severe forms fatal at birth to late 
infantile and juvenile/adult forms. Symptoms in the late 
onset forms are distinct. Patients uffer from slowly pro- 
gressing neurologic disease, dysmorphism and skeletal 
dysplasias and may survive into adulthood [333]. Most 
cases of the galactosialidosis have been found in Japan 
[88]. The majority of these Japanese patients uffer from a 
late onset form of the disease [88] 
Cloning of the cDNA of the protective protein showed a 
high degree of homology to serine carboxypeptidases from 
yeast and plants [84]. Expression studies of the cDNA 
revealed that the protective protein has serine esterase, 
deamidase and carboxypeptidase activity [281]. Surpris- 
ingly, a deamidase released from human platelets upon 
thrombin stimulation appears to be identical to the protec- 
tive protein [85,329]. This enzyme deamidates and inacti- 
vates a variety of biologically active peptides, whose C 
terminus is blocked by an amide bond (e.g. substance P, 
oxytocin, endothelin) [329]. It has two enzymatic activities 
with different pH optima. A deamidase activity is optimal 
at neutral pH and a carboxypeptidase activity at acidic pH. 
Further studies revealed that the protective protein is most 
likely identical to lysosomal cathepsin A [86,85,329]. The 
catalytic activity of this protease and its protective function 
for fl-D-galactosidase and neuraminidase activity are dis- 
tinct, since active site mutants are still able to restore the 
activity of these enzymes in galactosialidosis fibroblasts 
[86]. The stoichiometry of the three proteins in the com- 
plex is unclear. /3-D-galactosidase d ficiencies, in which 
no cross reacting material is found, demonstrate hat this 
enzyme is not an essential factor of the complex, since 
neuraminidase i  active in these cells. Cross reacting mate- 
rial negative mutants have not yet been identified among 
neuraminidase deficient cell lines, since neuraminidase 
deficiencies have not been analysed at the molecular level 
yet. The role of neuraminidase in complex formation is 
therefore unknown. The existence of different pools of 
fl-D-galactosidase and protective protein has been noted in 
several studies [86,87]. The majority of these proteins are 
present in the non complexed form, whereas only 20% are 
found within the complex. The fraction of protective pro- 
tein, which coimmunoprecipitates with fl-o-galactosidase, 
correlates with the amount of protective protein present in 
high molecular weight complexes as determined by gel 
filtration. The existence of different pools of protective 
protein and fl-D-galactosidase may be a consequence of
their function in different reactions. Within the complex 
the enzyme activities may act together to degrade glyco- 
proteins. Uncomplexed protective protein might act as a 
protease in the degradation of non glycosylated proteins 
and, depending on the local pH, as a deamidase in the 
inactivation of biologically active peptides. Uncomplexed 
/3-D-galactosidase may be involved in the degradation of 
sphingolipids, such as GM1 ganglioside and the mu- 
copolysaccharide k ratan sulfate. However, the existence 
of different pools of/3-D-galactosidase is speculative, since 
the current data cannot explain, why fl-D-galactosidase 
should be stable outside the protective protein complex. 
The complete structure of the gene of protective protein 
has not yet been published although a report of a partial 
gene structure has been reported [88]. Among late onset 
Japanese patients a splice donor site mutation of intron 7 
causing the skipping of exon 7 has been identified and it 
accounted for 28 of 38 mutant alleles examined [89]. 
However, this mutation seems to allow the production of a 
small amount of normal mRNA, explaining the mild phe- 
notype of the patients. Patients homozygous for this allele 
had a milder course of disease than genetic compounds 
with a null allele, a genotype phenotype pattern resembling 
that of other lysosomal storage diseases. Several mutations 
have been identified (see Fig. 4) and some have been 
analysed in more detail. A Phe-412 > Val was found in 
two late infantile patients [90]. This substitution renders 
the protective protein inactive with respect o its cathepsin 
activity and prevents dimerization of the protein. The lack 
of dimerization may be the cause for the retention and 
premature degradation of the mutant precursor in the ER. 
The retention, however, is not complete since some mutant 
protein becomes phosphorylated on mannose-6-phosphate 
residues and is properly sorted to the lysosomes [90]. 
Residual amounts of mature protective protein are present 
in lysosomes and this may explain the mild clinical pheno- 
type of the patient. When a cDNA having a mutation 
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Fig. 4. Structure of the protective protein eDNA and mutations causing 
galactosialidosis. N and C depict he amino and carboxyterminus, respec- 
tively. Mutations associated with mild phenotypes are shown on top, 
others at the bottom. Bold line depicts the most frequent allele found 
among Japanese patients. Numbers gives the frequency among Japanese 
patients. References are in parenthesis [89,90,286,287,330,395] 
found in a mild late infantile case (Tyr-249 >Asn) was 
transfected into deficient fibroblasts, a partial restoration of 
/3-D-galactosidase and neuraminidase activity could be 
demonstrated [287], indicating that low amounts of resid- 
ual protective protein may predispose for a milder course 
of disease. 
2.4. Fabry disease 
Fabry disease is an X linked disorder in which the 
enzyme C~-D-galactosidase A is deficient. This causes the 
storage of glycosphingolipids with a terminal o~-glycosidi- 
cally linked galactose, such as globotriaosylceramide, gal-
abiosylceramide [323] and blood group B glycolipids [324]. 
Deposition of these lipids occurs predominantly in vascu- 
lar endothelial, smooth and myocardial muscle cells and 
causes angiokeratomas of the skin and visceral disorders 
with renal and cardiovascular symptoms [378]. Pathology 
appears to be due to obstruction of small blood vessels by 
lipid storage and accumulation of lipids in myocytes. 
There is no involvement of the central nervous ystem, but 
patients typically suffer from episodic crisis of burning 
pain in the distal extremities, evere acroparesthisia and 
hypohidrosis caused by the involvement of the autonomic 
nerves. The onset of the disease is in childhood or adoles- 
cence [378]. Heterozygous female carriers may be healthy 
or display milder forms of disease. 
The eDNA [70] and the gene [71] have been cloned. 
The gene has 12 exons and is 14 kb long. It is charac- 
terized by an exceptionally high content of Alu sequences. 
Twelve repetitive Alu sequences have been identified, 
which cover more than 30% of the genomic a-D-galacto- 
sidase sequence. Since several deletions were detected in 
mutant alleles, it was assumed that the gene was prone to 
deletions due to illegitimate recombinational events be- 
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Fig. 5. Structure of the a-D-galactosidase A gene and mutations causing Fabry disease. Bars at the bottom indicate deletions or duplications. Mutations 
causing cardiac variant of Fabry disease are shown on the top. References are in parenthesis [69,72,75-78,80,81,247,301-303]. Numbers below the 
brackets indicate the exon in which the mutation is found. 
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tween Alu sequences. However, of 6 deletions analysed 
only one could be explained through Alu recombination, 
whereas the others occurred at short direct repeats [72,77] 
(see Fig. 5). 
In a particular form of Fabry disease the storage of 
lipids is confined to the myocardium. These patients may 
develop a hypertrophic cardiomyopathy or may only suffer 
from angina pectoris with otherwise normal hemodynamic 
functions [73-75]. Five different mutations of a-D-galacto- 
sidase A have so far been described in these late onset 
patients, a Asn-215 > Ser [303], a Gin-279 > Glu [69], a 
Met-296 > Val [75], a Arg-301 > Gin substitution [76] and 
an 3 bp in frame deletion causing the loss of Arg-404 or 
405 [303], respectively. All these mutations are localized 
in the carboxyterminal halve of the molecule. A consider- 
able amount of residual enzyme activity (up to 25% when 
measured with an artificial substrate) has been found in 
these patients with the cardiac variant of Fabry disease 
[75]. Overexpressed a-D-galactosidase A bearing the Gin- 
279 > Glu or the Arg-301 > Gin substitutions still has 5% 
and 15% of enzyme activity towards an artificial substrate, 
respectively [69]. Thus, residual enzyme activity seems to 
predispose for the cardiac variant. It may suffice to prevent 
storage in endothelial and renal cells, but is insufficient o 
protect he heart. 
The Gin-279 > Glu substituted enzyme has been char- 
acterized in more detail. While its kinetic properties are 
similar to the normal enzyme, the mutant is thermolabile in
vitro at 37°C and neutral pH, but shows an increase in 
stability at lower temperatures or acidic pH. The thermola- 
bility is not just an in vitro phenomenon, since three times 
more enzyme activity can be expressed from the mutant 
cDNA transfected into COS cells, when these cells were 
grown at 30°C. Since these two conditions - 37°C and 
neutral pH - also apply to the prelysosomal compartments 
in vivo, the in vitro observations may be explain an 
instability of the mutant enzyme in an early biosynthetic 
compartment [280]. 
2.5. Niemann Pick disease 
Niemann Pick disease type A and B are caused by a 
deficiency of the enzyme acid sphingomyelinase [340]. 
This enzyme hydrolyses phingomyelin to ceramide and 
phosphorylcholine. In addition a nonlysosomal neutral sph- 
ingomyelinase has been described, but this enzyme is not 
affected in Niemann Pick disease [341]. Deficiency of the 
lysosomal enzyme causes storage of sphingomyelin [340]. 
Two types of disease can be distinguished an acute type A 
and a chronic type B. (Recently, a new designation has 
been suggested, in which type A is termed IA and type B 
is termed IS) [340]. The acute form is a severe disorder of 
infancy characterized by progressive psychomoter retarda- 
tion, massive visceromegaly and death by 3 years of age. 
The chronic form is characterized by a visceromegaly, but 
little involvement of the nervous system and survival into 
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Fig. 6. Structure of the sphingomyelinase gene and mutations causing 
Niemann Pick Type A and B disease. Labelling of mutations i as 
indicated inFig. 1 and 2. Bold lines indicate the most frequent defective 
alleles among Ashkenazi Jews. References are in parenthesis [101- 
104,248-250]. Numbers give frequencies. Niemann Pick Type B muta- 
tions are indicated on top. 
adulthood. Accordingly, the two types of disease are termed 
neuronopathic (type A) and nonneuronopathic (type B). 
The disease is panethnic, but has a higher frequency 
among Ashkenazi Jews. The cDNA [99] and the gene [100] 
of sphingomyelinase have been cloned. Three mutant alle- 
les have been found to be most frequent among Ashkenazi 
Jews (see Figs. 6 and 7). Two alleles show amino acid 
substitutions - Leu-302 > Pro and Arg-496 > Leu - and 
account for 23% and 30% of mutant alleles, respectively 
[101]. The third has a deletion of a C in codon 330 causing 
premature termination and represents about 8% of defec- 
tive alleles in Ashkenazi Jewish patients. Introduction of 
the amino acid substitutions into the wild type cDNA and 
their expression revealed a complete loss of enzymatic 
activity. These alleles have, so far, not been found outside 
the Jewish population. Patients, who were homozygous or 
genetic compounds for these alleles, always suffered from 
the acute type A form of Niemann Pick disease. 
Three mutations have been found in milder Niemann 
Pick type B disease. A deletion of a single codon eliminat- 
ing Arg-608 has initially been characterized in Ashkenazi 
Jews [102]. Two Ashkenazi type B patients were studied 
and both were genetic ompounds for this allele. The same 
allele was shown to be the prevalent mutation in Niemann 
Pick type B patients of Northern African origin [288]. The 
allele could not be detected among type A patients. In 
fibroblasts of patients being homozygous or genetic com- 
pounds for this allele a considerable residual enzyme 
activity could be detected towards the natural substrate in 
vitro and in situ in cultured fibroblasts [288]. A Japanese 
patient was found to be homoallelic for a Ser-436 > Arg 
substitution [250] and a European type B patient was a 
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Fig. 7. Structure of the arylsulfatase A gene and mutations causing 
metachromatic leukodystrophy. Bold lines depict the most frequent alleles 
among Caucasians. The mutations of the pseudodeficiency allele are 
indicated in bold letters. Both mutations are found in the same allele. 
Disease causing mutations found on the background of the pseudodefi- 
ciency allele are shown in italics. Mutations associated with late onset 
disease are shown on top, others at the bottom. References are in 
parenthesis [106,109,110,113,115-119,244,251,289,290,297,298,344]. 
genetic ompound for a Niemann Pick type A allele and an 
allele carrying a Gly-242 > Arg substitution [103]. In vitro 
mutagenesis of the sphingomyelinase cDNA and expres- 
sion studies of the Gly-242 > Arg substituted enzyme re- 
vealed a substantial residual enzyme activity (40% of 
control determined with a synthetic substrate) encoded for 
by this allele [103]. Thus, it seems that the nonneurono- 
pathic form is found in patients being homozygous or 
genetic ompounds for alleles encoding for mutant enzyme 
with some residual activity. 
In addition to Niemann Pick type A and B there is a 
third clinically similar form termed type C. Cells from 
these patients how an impaired intracellular transport of 
cholesterol from lysosomes, but the primary defect is not 
in the sphingomyelinase g ne and has so far not been 
elucidated (for review see [342]). 
2.6. Metachromatic leukodystrophy 
The deficiency of arylsulfatase A causes metachromatic 
leukodystrophy. The substrate of this enzyme is cerebro- 
side-3-sulfate (sulfatide). This glycolipid is mainly found 
in the myelin sheaths of the nervous ystem. Deficiency of 
arylsulfatase A causes storage of sulfatide in various or- 
gans, but the disease mainly affects the nervous system 
[343]. Patients suffer from progressive demyelination, 
which leads to a variety of neurologic symptoms and 
finally causes death. Typically the disease starts with gait 
disturbances at the age of 18 to 24 months, in the further 
course of disease patients develop a spastic tetraparesis, 
seizures and dementia. In the milder late onset forms 
psychiatric symptoms frequently prevail initially before 
neurologic symptoms become apparent [343]. 
Arylsulfatase A is encoded in a small gene [105], and 
the entire coding sequence of 1.5 kb is distributed over 8 
exons and encompasses not more than 3 kb of genomic 
sequence (see Fig. 7). Two mutant alleles are particularly 
frequent and account each for about 25% of mutant alleles 
among Caucasian patients [106,107]. One of these alleles 
has a splice donor site mutation at the exon/intron 2 
border and causes a complete loss of arylsulfatase A
mRNA. In the other allele a Pro-426 > Leu substitution is
found, which allows for the normal synthesis of catalyti- 
cally active enzyme, which is highly unstable upon arrival 
in the lysosome [108]. The high frequencies of these alleles 
have allowed their detection in a number of patients and 
have revealed a simple genotype phenotype correlation. 
Homozygosity for the splice donor site mutation causes the 
severe late infantile form of the disease, heterozygosity for 
the splice donor site mutation and the Pro-426 > Leu allele 
mitigates the course of the disease to the juvenile form and 
homozygosity for the Pro-426 > Leu allele is mostly found 
in the mildly affected adult patients. This genotype-pheno- 
type correlation can be explained by the low residual 
enzyme activity associated with the Pro-426 > Leu allele, 
in which one copy of this allele mitigates the course of the 
disease and the gene dosage effect of two alleles causes 
the still milder adult form of metachromatic leukodystro- 
phy. A correlation between the clinical phenotype and the 
residual enzyme activity has also been demonstrated in a 
study in which the residual enzyme activity was deter- 
mined by feeding sulfatide to cultured fibroblasts of pa- 
tients with different severity of disease. Higher residual 
enzyme activities were found in cells of mildly affected 
adult patients [234]. 
Except for the Thr-274 > Met allele, which has been 
found in high frequency among Australians of Lebanese 
origin [251] all other alleles characterized so far have only 
been found in one or few patients, which shows that the 
disease is genetically heterogeneous [109]. 
Although residual enzyme activity is one of the impor- 
tant determinants of the clinical phenotype one patient has 
been identified, who suffered from the severe late infantile 
form of the disease but had considerable residual enzyme 
activity. When tested with the natural substrate of arylsul- 
fatase A, cultured fibroblasts of this patient metabolized 
cerebroside sulfate at higher rates than fibroblasts of pa- 
tients with the mild adult forms of the disease. The appar- 
ent discrepancy of the residual enzyme activity and the 
phenotype of this patient may be explained by cell type 
specific differences in the expression of the defect. Since 
metachromatic leukodystrophy is a disease of oligodendro- 
cytes, the expression of the defect may be different in 
those cells than in cultured fibroblasts. The mutation found 
in this patient was a Gly-309 > Ser substitution, which 
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caused a reduced intralysosomal stability of the mutant 
enzyme [110]. 
Deficiency of arylsulfatase A has also been demon- 
strated in healthy individuals at high frequency (up to 
2.6% of the population) [107,345]. The deficiency is sub- 
stantial, but since it is not complete it does not cause a 
disease and is another example of lysosomal enzyme pseu- 
dodeficiency [111]. As indicated above, pseudodeficiencies 
have also been described for various lysosomal enzymes 
[386] such as /3-hexosaminidase a and fl-subunits, and 
seem to be quite frequent in the /3-D-galactocerebrosidase 
gene [112], which is defective in Krabbe disease. Arylsul- 
fatase A pseudodeficiency is caused by homozygosity for a 
frequent allele that due to a mutation in a polyadenylation 
signal supports only the synthesis of about 10% of arylsul- 
fatase A compared to the normal allele [113]. The fre- 
quency of this allele is estimated to be 7-15% [107,345]. 
Whereas homozygosity for the pseudodeficiency allele is 
not associated with a disease, it has been a matter of 
debate whether heterozygosity for a pseudodeficiency al-
lele and a metachromatic leukodystrophy allele, may be 
the cause of neurologic disease in these persons. The allele 
frequencies of metachromatic leukodystrophy alleles and 
the pseudodeficiency allele allow to calculate that about 1 
in 1000 individuals hould be a genetic compound for 
these two alleles. Sixteen such genetic compounds have 
been examined clinically and radiologically. Neurologic 
symptoms or radiologic alterations have been found in 
three of the probands. However, neither the neurologic 
symptoms nor the radiologic findings resembled those seen 
in metachromatic leukodystrophy patients. This study 
demonstrates that the majority of these genetic ompounds 
will not develop a progressive neurologic disease [114]. 
However, since the oldest person examined was 56, it can 
not be excluded that some might develop a senile form of 
metachromatic leukodystrophy in old age. 
In comparison, /3-hexosaminidase a subunit pseudode- 
ficiencies and, on the other hand, /3-hexosaminidase /3- 
subunit and arylsulfatase A pseudodeficiencies arefunda- 
mentally different. Whereas /3-hexosaminidase A pseudod- 
eficiency is caused by a reduced activity towards the 
artificial substrates and can thus be attributed to a change 
of catalytic properties [37,38], /3-hexosaminidase /3-sub- 
unit and arylsulfatase A pseudodeficiencies are due to 
diminished mRNA levels causing reduced synthesis of 
enzymes [53,113]. 
2.7. Gaucher disease 
Gaucher disease is caused by the deficiency of /3-0- 
glucocerebrosidase [347]. The enzyme hydrolyses glucose 
from the sphingolipid glucosylceramide [347]. Glucosylce- 
ramide is an intermediate compound in the synthesis and 
degradation of complex glycosphingolipids. Deficiency of 
the enzyme causes torage of glucosylceramide mainly in 
cells of the monocyte/macrophage system [348]. Gener- 
ally, the disease affects the bone marrow, bone, spleen, 
and liver, causing anaemia, thrombocytopenia, bone le- 
sions and hepatosplenomegaly. In the less frequent, more 
severe forms of the disease, the central nervous ystem is 
also affected and, as in Niemann Pick disease, these 
variants have been termed neuronopathic. The severe neu- 
ronopathic form (type II disease) is rare and occurs paneth- 
nically. It presents with hepatosplenomegaly andneuronal 
complications [348]. The clinical presentation is quite uni- 
form and death usually occurs before 2 years of age. The 
mild nonneuronopathic form (type I disease) is frequent 
among Ashkenazi Jews and is clinically heterogeneous. 
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Fig. 8. Structure of the fl-D-glucocerebrosidase gene and mutations causing Gaucher disease. Designation of mutations i as indicated in Fig. 1. Mutations 
causing mild type of disease are shown on top. Bold lines depict he most frequent alleles and numbers give the frequency of these alleles in Jewish/non 
Jewish communities, respectively. References are in parenthesis [123,126,129,131,135-137,139,237,304,385,393-396]. 
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Symptoms may develop in childhood or not until old age 
and many patients are only diagnosed by chance since 
their symptoms are so mild that they do not seek medical 
advice [125]. In this mild Gaucher type I disease, the most 
frequent sign is hepatosplenomegaly with pancytopenia 
and in the course of the disease disabilities due to bone 
deformities develop [348]. A third intermediate form of 
Gaucher disease (type III) is a so called subacute neurono- 
pathic form, which, due to its high frequency in a Swedish 
isolate, has also been termed Norbottnian type Gaucher 
disease [140]. Patients show neuronal as well as visceral 
involvement, but the neurological symptoms develop later 
and more slowly than in the acute neuronopathic form. 
The cDNA, the gene and pseudogene of /3-D-glucocere- 
brosidase have been cloned [120,121]. The pseudogene is
tightly linked to the normal gene, but is smaller due to 
several mainly intronic deletions. Thirty six different muta- 
tions have been characterized [349] (see Fig. 8). Most of 
these mutations are rare and some are limited to single 
families. However, five of the mutant alleles account for 
more than 98% of defective/3-D-glucocerebrosidase allel s 
among Ashkenazi and for about 70% of mutant alleles 
among non Jews [123,292]. 
Homozygosity or heterozygosity for the Asn-370 > Ser 
allele precludes the development of neurologic symptoms 
and is always associated with the type 1 nonneuronopathic 
form of the disease [349]. Asn-370 > Ser homozygotes 
have late onset of disease -median 30.8 years, (combina- 
tion of data from [122] and [124])-, whereas genetic 
compounds for this allele and the 84GG allele, which has a 
G insertion causing a frameshift and is thought o be a null 
allele, develop symptoms earlier with a median of 7.4 
years. However, among patients with identical genotypes 
the range of age of onset can be enormous: 3-73 years for 
Asn-370 > Ser homozygotes and 2-28 years Asn-370 > 
Ser/84GG heterozygotes. Thus disease of a Asn-370 > Ser 
homozygote can be more severe than that of a genetic 
compound. It has also been shown that about two thirds of 
the Asn-370 > Ser homozygotes have such a mild form of 
disease that they do not seek medical advice and remain 
undiagnosed [125]. 
Among non Jews the most frequent allele has a Leu-444 
> Pro substitution [123]. Homozygosity for this mutation 
has been found in patients uffering from all three types of 
disease. From a total of 44 homozygous patients - sum- 
mary of patients mentioned in references [126], [127], 
[140-144] and [291] - 11 had type I, 9 type II and 24 type 
III disease. These numbers show that the majority of 
homozygotes do have neurologic symptoms, but why about 
25% suffer from the nonneuronopathic type I disease is not 
clear. Given identical fl-D-glucocerebrosidase alleles the 
genetic background may influence the type of disease 
which will develop. Most of the Leu-444 > Pro homozy- 
gous type I patients were of Japanese origin, whereas most 
with type III disease were of Swedish specifically Norbott- 
nian origin. It has been objected that the Japanese type I 
patients were diagnosed at young age and that it cannot be 
excluded that they will develop neurologic symptoms in 
the near future, which would classify them as type III 
patients [349]. However, the fact that patients from differ- 
ent ethnic origin suffer from different ype of disease or at 
least from a different course of the same variant of the 
disease points to other genetic or epigenetic factors that 
may influence the outcome of disease. This may resemble 
the situation in other lysosomal storage diseases uch as 
Sandhoff disease, where the same allele in a Japanese and 
a French Canadian patient was associated with similarly 
varying phenotypes [50,51]. 
In many alleles the Leu-444 > Pro substitution is pre- 
sent as a single point mutation. However, the same amino 
acid substitution can be found in the /3-D-glucocerebrosi- 
dase pseudogene. Recombination orgene conversion events 
between the gene and the pseudogene can introduce this 
mutation into the fl-19-glucocerebrosidase gene. Since the 
Leu-444 > Pro substitution is not the only difference be- 
tween the gene and the pseudogene, a number of other 
mutations will be introduced at the same time. The number 
depends on the site of recombination. The existence of two 
such recombination alleles - termed RecNci and Rec TL - 
carrying the Leu-444 > Pro substitution has been demon- 
strated [127-129]. These alleles show recombination at 
different sites and introduce 1 (Ala-456 > Pro) or 2 (Ala- 
456 > Pro and Asp-409 > His) additional mutations into 
the gene. These alleles have been termed complex alleles. 
It is interesting to note, that five patients [127,130] who 
have been identified as genetic compounds for a Leu-444 
> Pro and a complex allele suffered from severe type II 
disease, but that this kind of heterozygosity has so far not 
been described among type I and type III patients. Further- 
more, not a single patient with type II disease has been 
identified, who has unambiguously been shown to be a 
Leu-444 > Pro homozygote [349]. Although the number of 
patients in which Leu-444 > Pro carrying alleles have been 
differentiated is low, preventing definitive conclusion to be 
drawn, the data suggest that a genetic compound of a 
Leu-444 > Pro point mutation allele and complex allele 
may suffer from a more severe type of disease. 
The 84GG allele [131], characterized by an insertion of 
a G in exon 2 is thought to be a null allele, since the 
mutation causes a frameshift, which prevents the synthesis 
of any functional /3-D-glucocerebrosidase. Interestingly, no 
84GG homozygotes have yet been described. The Gaucher 
mice that have recently been generated by homologous 
recombination of murine embryonic stem cells, are ho- 
mozygous for a null allele [132]. They displayed such a 
severe phenotype such that they died one day after birth. 
Severe neonatal forms of Gaucher disease have been de- 
scribed [265] and assuming a similar genotype-phenotype 
correlation in mice and man, it can be speculated that 
severe neonatal forms of Gauchers may be homozygous 
for null alleles (e.g. 84GG alleles). 
The effects of the Asn-370 > Ser and the Leu-444 > Pro 
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mutations on the fl-D-glucocerebrosidase enzyme have been 
investigated by expression of cDNA's encoding poly- 
peptides with these substitutions. The Leu-444 > Pro sub- 
stituted enzyme is highly unstable and has a 10-fold higher 
Vm~ x towards an artificial substrate [133]. Cells transfected 
with the Asn-370 > Ser cDNA showed /3-D-glucocere- 
brosidase polypeptides, the specific activity of the enzyme 
towards a synthetic and a natural substrate was 2-5-fold 
decreased [134]. For optimal enzymatic activity fl-D-gluco- 
cerebrosidase has to be activated by an activator protein 
(see chapter on saposin activator proteins). The mode of 
action is not a solubilization of the substrate as in the case 
of GM2 activator protein, but rather a direct stimulation of 
enzyme activity. It could be demonstrated that in vitro the 
Asn-370 > Ser substituted enzyme is less effectively stim- 
ulated by the activator than the normal enzyme [133]. 
2.8. Sphingolipid activator protein deficiencies 
Several enzymes involved in the degradation of sphin- 
golipids depend on the assistance of small acidic proteins 
to hydrolyse their substrates. These Sphingolipid Activator 
Proteins are now called saposins (SAPosin). Five different 
saposins are encoded by two different genes. One gene 
codes for the GM2 activator protein and has already been 
discussed in the GM2 gangliosidoses section. The other 
four saposins, which have been designated A, B, C and D 
are encoded by a single gene [145,146]. They are synthe- 
sized as a common precursor polypeptide (prosaposin), 
which is proteolytically cleaved in the lysosome to yield 
the four independent, but structurally homologous proteins 
[147]. The mechanism by which saposin B acts resembles 
that of the GM2 activator protein, in that it solubilizes 
sulfatide for the desulfation by arylsulfatase A [148]. How- 
ever, saposin B seems not to be specific for the degrada- 
tion of sulfatide by arylsulfatase A, since it has also been 
shown to activate the hydrolysis of other lipids by other 
enzymes [357]. Saposin C has been shown to activate 
/3-D-glucocerebrosidase, however, as indicated above this 
occurs not by solubilization of the substrate, but via direct 
interaction and stimulation of the enzyme [149]. The acti- 
vation of arylsulfatase A and fl-D-glucocerebrosidase by 
saposin B and C, respectively, has initially been shown in 
vitro, but its in vivo significance has been demonstrated by 
the existence of genetic diseases due to mutations affecting 
the saposin B and C domain of the precursor protein 
causing selective deficiencies of one of these saposins (see 
Fig. 9). Mutations in saposin B cause a variant form of 
metachromatic leukodystrophy, whereas mutations in the 
saposin C domain have been found in a patient with a 
variant form of Gaucher disease [160,164]. Metachromatic 
leukodystrophy caused by saposin B deficiency is clini- 
cally similar to an arylsulfatase A deficiency. However, 
the fact that saposin B also activates the hydrolysis of 
other lipids by different enzymes is reflected by the com- 
position of the storage material, which in addition to 
sulfatide contains globotriaosylceramide and GM 3 gan- 
glioside in saposin B deficiencies [358]. Saposins A acti- 
vates the hydrolysis of glucosylceramide by /3-D-gluco- 
sylcerebrosidase and of galactosylceramide by fl-D-galac- 
tocerebrosidase [149,357]. Saposin D has been considered 
as an sphingomyelinase activator [356], but it has recently 
also been shown to inhibit this enzyme [273]. Since defi- 
ciencies of these proteins, which should cause variant 
forms of Gaucher and Niemann Pick disease, respectively, 
have not been described their in vivo function remains 
unclear. Because saposin C deficiencies cause Gaucher 
disease in the presence of saposin A, one can conclude that 
the latter cannot complement the defective saposin C and 
does not interact with fl-D-glucocerebrosidase in vivo. 
Further clues about he in vivo function have come from a 
patient in whom, due to a mutation in the initiation codon, 
the entire precursor protein and, thus, all four saposins are 
deficient [150,151]. Shortly after birth this patient pre- 
sented with hyperkinesia, respiratory insufficiency and 
hepatosplenomegaly nd died at the age of 16 weeks. 
Fibroblasts howed a substantial deficiency of /3-D-galac- 
tocerebrosidase, fl-D-glucocerebrosidase nd ceramidase. 
Storage of the substrates of these enzymes could be 
demonstrated in the patients liver [150]. Sphingomyelinase 
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Fig. 9. Structure of and mutations in the prosaposin gene. Mutations causing a variant form of metachromatic leukodystrophy are shown in italics, the one 
causing Gaucher disease in bold letters. Question mark indicates that exon one has not been analyzed on the genomic level yet. References are in 
parenthesis [151,160,162-164] 
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activity was normal and there was no storage of sphingo- 
myelin, which suggest hat, in vivo, saposins are not 
essential for sphingomyelinase activity. 
Evidence is accumulating, that saposins and particularly 
the prosaposins, may have functions other than just the 
activation of hydrolases. Prosaposin has been identified in 
various secretory fluids like cerebrospinal fluid, seminal 
fluid, bile and milk. In the latter the amount changed 
during the lactation period [152]. Prosaposin is secreted by 
platelets upon stimulation with thrombin [153]. In vitro 
studies have shown that saposin B is able to transfer a 
variety of sphingolipids from donor to acceptor liposomes 
in vitro [154]. Prosaposin binds gangliosides with high 
affinity and is also able to transfer gangliosides from donor 
to acceptor membranes [155]. Thus, these proteins may act 
in a more general way as lipid transfer proteins. 
Saposins have been shown to accumulate in tissues of 
patients with lysosomal storage disease. As much as 100- 
fold levels of saposin A were found in the liver of fucosi- 
dosis patients [263]. Saposins accumulated to various ex- 
tents in patients with GM1 gangliosidosis, Tay Sachs, 
Sandhoff, Gaucher and Niemann Pick disease. It is not 
clear whether the accumulation is due to a reduced break- 
down or to an enhanced synthesis of the prosaposin 
molecule [263]. 
The cDNA and the gene for the saposin precursor have 
been cloned [145,157-159]. Five mutations causing three 
different diseases have been described (see Fig. 9). As 
indicated earlier a mutation in the initiation codon Met-1 
> Leu leads to a deficiency of all saposins causing a 
severe disease with early death of the patient [150,151]. 
Three mutations have been found in the saposin B domain. 
All these mutations cause a variant form of metachromatic 
leukodystrophy. These include the loss of a potential 
glycosylation site due to a Thr-217 > lie substitution 
[160,161] and the substitution ofa cysteine (Cys-241 > Ser) 
[162], which is conserved among all four saposins. A point 
mutation in intron 7 creates an alternative splice site 
causing a 33 bp insertion [163]. Finally, a point mutation 
in the saposin C domain has been found in a patient with 
Gaucher disease [164]. Like in the mutant saposin B allele 
substitution of a conserved cysteine (Cys-385 > Phe) might 
destroy a functionally important disulfide bridge. 
2.9. Wolman disease 
Deficiency of lysosomal acid lipase results in intralyso- 
somal storage of cholesteryl esters and triacylglycerols and 
causes two clinically distinguishable diseases: Wolmans 
disease and cholesteryl ester storage disease (CESD) [346]. 
Whereas Wolmans disease becomes apparent in early in- 
fancy by hepatosplenomegaly, various gastrointestinal 
problems, anaemia, calcification of the adrenal glands and 
is usually lethal in the first year of life, CESD is milder 
and age at onset is later. A variety of different symptoms 
have been described in CESD patients [346]. However, all 
patients howed hepatomegaly, which in some cases lead 
to hepatic fibrosis and liver failure [346]. Due to the low 
abundance, the purification of the enzyme and the cloning 
of the cDNA has been difficult, but has recently been 
achieved [170]. The cDNA of acid lipase is 2.6 kb long 
and the open reading frame predicts a protein of 372 
amino acids. It shows a high homology when compared to 
human gastric lipase. When both enzymes are compared 
58% of amino acid residues are identical. The gene of 
lysosomal acid lipase is divided into 10 exons and encom- 
passes about 36 kb of genomic sequence [359,360]. So far 
three mutations causing Wolman disease or CESD have 
been described. A splice donor site G > A substitution at 
the 3' end of exon 8 has been found in a patient with 
CESD resulting in a 72 bp exon deletion coding for amino 
acid 254-277 [361]. A patient with Wolman disease was a 
genetic ompound of an allele, which due the insertion of a 
T is associated with premature termination of the mutant 
protein, and an allele with a Leu-179 > Pro substitution 
[360]. The reasons why some patients develop Wolman 
disease and others CESD are not yet clear. 
2.10. Krabbe disease 
Krabbe disease or globoid cell leukodystrophy is due to 
the deficiency of fl-D-galactocerebrosidase [371]. The en- 
zyme releases galactose from galactocerebroside, one of 
the major membrane lipids of the myelin sheaths. Like in 
metachromatic leukodystrophy patients uffer exclusively 
from neurologic symptoms [371]. They present in the first 
six months of life with hyperirritability owards external 
stimuli, hyperaesthesia, spasticity and regression of neuro- 
logic development. Patients usually die before their second 
year of life in a decerebrate state [371]. In addition late 
onset forms have been described. The cloning of the gene 
has been difficult due to the low abundance and hydro- 
phobicity of the enzyme, but has recently been achieved 
[296,405]. The purified enzyme has a molecular weight of 
51 kDa. The cloned cDNA has 3795 nucleotides, 2007 of 
which represented an open reading frame, predicting a 
protein of 669 amino acids [296]. Although the substrates 
of /3-D-glucocerebrosidase and /3-D-galactocerebrosidase 
are structurally similar, no sequence homology between 
the two enzymes has been found. A nonsense mutation 
was found at codon 369 (GAA > TAA) in the coding 
sequence of cDNA amplified from cultured skin fibroblast 
mRNA from a patient with typical Krabbe disease [405]. 
3. Disorders of glycoprotein degradation 
3.1. Fucosidosis 
Fucosidosis is caused by a deficiency of the enzyme 
C~-L-fucosidase, which cleaves fucose residues in various 
substrates. Fucose is found in N- and O-linked oligo- 
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saccharide side chains of sphingolipids, blood group anti- 
gen containing lycolipids and glycopeptides and the mu- 
copolysaccharide k ratan sulfate [171,388]. Intermediates 
of N-linked oligosaccharide degradation represent the ma- 
jority of storage compounds in fucosidosis [171]. Most of 
the intermediates are fucosylated glycopeptides and gly- 
coasparagines, while few are oligosaccharides [171]. In- 
creased urinary excretion of keratan sulfate has also been 
reported [388]. Among the stored glycolipids blood group 
H containing lycolipids have been identified [171]. Two 
types of fucosidosis can be distinguished. Type I starts in 
the first year of life and shows a rapid neurological 
deterioration, coarse facies, dysostosis multiplex and causes 
death within the first decade of life. Type II fucosidosis is 
more frequent than type I, and develops later in life. 
Symptoms are similar to type I, but progress more slowly 
and in addition the patients typically develop angioker- 
atoma diffusum. These patients may survive into the fourth 
decade of life [171]. Intermediate types of disease have 
also been described [171]. The cDNA [172], the gene and a 
pseudogene of a-L-fucosidase have been cloned [173]. So 
far, 12 defective Ot-L-fucosidase alleles have been de- 
scribed (see Fig. 10). The most frequent allele has a 
premature termination codon at amino acid position 422 
(Gin > ter) and accounts for 20% of all mutant C~-L- 
fucosidase alleles [175]. In accordance with the existence 
of both types of disease in the same family, patients 
homozygous for the Gin > ter-422 allele have been found 
among type I as well as type II patients [171]. Interest- 
ingly, so far only one allele with an amino acid substitu- 
tion Gin-281 > Arg has been found [176], another has a 
splicing defect [253] and all others show premature termi- 
nation due to the small deletions or introduction of termi- 
nation codons [174,252]. 
3.2. Aspartylglucosaminuria 
The final step in the hydrolysis of N-linked oligo- 
saccharide side chains of proteins is the cleavage of the 
bond between N-acetylglucosaminylamine and asparagine. 
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Fig. 11. Structure ofthe L-aspartyl-D-glucosaminidase gene and mutations causing aspartylglucosaminuria. The bold line indicates the mutation i Fins and 
its frequency in Finnish patients. References are in parenthesis [178,182,185-187]. 
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This reaction is catalysed by glycoasparaginase (N4-( fl- 
N-acetylglucosaminyl)-L-asparaginase). Deficiency causes 
the accumulation of aspartyl-N-glucosamine in various tis- 
sues [380]. Patients typically suffer from mental retarda- 
tion, which becomes apparent in between the age of 1 and 
4 years. Patients usually die of pulmonary complications at
the age of 30 to 50 years [380]. The clinical phenotype is
uniform and no clinical subtypes can be distinguished, 
which in this respect makes the disease unique among 
lysosomal storage disorders [380]. The disease occurs 
panethnically, but shows a particularly high frequency in 
the Finnish population [178,380]. The cDNA [177,178] and 
the gene of the enzyme have been cloned [179] and a 
number of mutations have been described [180] (see Fig. 
11). The mutant allele found in the Finnish isolate has two 
amino acid substitutions one codon apart (Arg-161 > Gin 
and Cys-163 > Ser) and accounts for 98% defective alleles 
among Fins [178]. Expression studies revealed that only 
the Cys-163 > Ser substitution is responsible for the en- 
zyme deficiency, whereas the Arg-161 >Gln substitution 
is a polymorphism [181]. Cys-163 is involved in the 
formation of a disulfide bond in the normal enzyme and its 
substitution is likely to cause a misfolding of the polypep- 
tide [362]. In 9 non Finnish patients of different ethnic 
origin, 9 different mutant alleles have been found demon- 
strating the heterogeneity of the disease [182]. Eight of the 
patients were homozygous, which suggests that most came 
from consanguineous marriages. In one patient a deletion 
occurred in the 3' untranslated region of the cDNA [183]. 
No mutation was found in the coding sequence. Although 
the mutant RNA was smaller, its amount was comparable 
to normal RNA levels. However, glycoasparaginase poly- 
peptides could not be detected, suggesting that the mutant 
RNA was translationally inactive. Expression of the cDNA 
carrying the same deletion in COS cells yielded normal 
enzyme activities. Thus, the mechanism by which this 
mutant causes the deficiency remains obscure [183]. 
The pattern of proteolytic maturation of glycoasparagi- 
nase is unique among lysosomal enzymes. Lysosomal 
enzymes are usually proteolytically cleaved within the 
lysosome, but processing of glycoasparaginase starts al- 
ready in the ER [184]. Shortly after synthesis the inactive 
42 kDa precursor is cleaved into the active 27 kDa/17 
kDa dimeric enzyme. After the arrival in the lysosome the 
27 kDa subunit is further trimmed by a removal of 10 
amino acids at the carboxyterminus [184]. Since the en- 
zyme is also active at neutral pH, the activation of the 
enzyme in the ER could also be functionally important. 
3.3. Schindler disease 
a-N-acetylgalactosaminidase has long been charac- 
terized as a lysosomal activity [352,406], but patients 
suffering from a lysosomal storage disease due to the 
deficiency of this enzyme have only recently been de- 
scribed [91,93,407]. The enzyme hydrolyses a-glycosidi- 
cally linked N-acetylgalactosamine residues from synthetic 
substrates, oligosaccharides, glycolipids and glycopeptides 
[339]. Such residues can be found in glycolipids containing 
blood group A specifying trisaccharides [350], keratan 
sulfate from cartilage [351], N-linked [352,353] and O-lin- 
ked oligosaccharides [352,353]. 
Initially urine from the older affected German sibling 
was analyzed and a 5-fold elevated accumulation of blood 
group A trisaccharide was detected [354]. Since the brother 
of this patient was blood group 0 and did thus not excrete 
blood group A trisaccharide, but suffered from an even 
more severe type of disease, the storage of blood group A 
trisaccharide cannot be a major determining factor in the 
pathogenesis of the disease [355]. Further analysis of pa- 
tients urine identified an approx. 100 times elevated uri- 
nary excretion of compounds in which oligosaccharides 
were O-glycosidically linked to amino acids or peptides 
[94,355]. Thus, c~-N-acetylgalactosaminidase deficiency is 
a disorder of O-glycan catabolism. Interestingly, the major 
oligosaccharides had no ot-N-acetylgalactosaminyl residues 
at their nonreducing terminals, but neuraminic acid 
[94,355]. Thus, in vivo, the enzyme may act as an endogly- 
cosidase and neuraminidase may only desialylate oligo- 
saccharides after endoglycolytic cleavage has occurred, 
however no satisfying explanation has been found. 
In 1989 the disease was described in two sons of a 
consanguineous [91] couple and has been called Schindler 
disease [378]. The patients howed a variety of neurologic 
symptoms. The disease started by a loss of acquired skills 
and a psychomotor regression in the second year of life. 
Patients developed cortical blindness, seizures and spastic- 
ity. Examination of the central and peripheral nervous 
tissue revealed spheroid bodies in terminal axons, which 
classified the disease as a neuroaxonal dystrophy [91]. 
Already in 1987, a Japanese 46-year-old woman was de- 
scribed, who suffered from disseminated angiokeratoma, 
but showed no neurologic involvement [92]. 3 years later 
the patient was shown [93,407] to be ot-N-acetylgalac- 
tosaminidase deficient and thus suffered from late onset 
form of the disease. These examples demonstrate he re- 
markable clinical variability of the disease. The cDNA 
[96,97,408] and the gene [95] of the enzyme have been 
cloned. The nucleotide sequence predicts a protein of 411 
amino acids. The amino acid sequence and the gene struc- 
ture shows a strong homology to Ot-D-galactosidase A 
suggesting a common evolutionary origin of both enzymes 
[96,97,408]. Analysis of mRNA of two affected children 
revealed a Glu-325 > Lys substitution. No enzyme activity 
could be expressed from a cDNA encoding an enzyme 
with these mutations [98]. Biosynthetic studies in fibrob- 
lasts revealed efective phosphorylation f the precursor 
polypeptide, absent maturation and rapid intracellular 
degradation [409]. The mutation in the adult onset patient 
is a single C > T transition resulting in the amino acid 
substitution Arg-329 > Trp [410]. 
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4. Mucopolysaccharidoses 
4.1. Mucopolysaccharidosis type I/Hurler Scheie syn- 
drome 
Mucopolysaccharidosis type I (MPS I) is caused by the 
deficiency of a-L-iduronidase. This enzyme cleaves termi- 
nal iduronic acid residues from the glycosaminoglycans 
heparan and dermatan sulfate [381]. Deficiency causes 
storage and urinary excretion of these undegraded or par- 
tially degraded mucopolysaccharides [381]. The spectrum 
of clinical phenotypes i  broad. In the severe form, patients 
typically show symptoms in the first year of life presenting 
with hepatosplenomegaly, skeletal dysplasias, corneal 
clouding, short stature and mental retardation. These se- 
vere forms have been termed Hurler syndrome. At the 
other end of the clinical spectrum are the patients with 
mild form of disease termed Scheie syndrome. They have 
little or no neurologic involvement, have mild hep- 
atosplenomegaly, joint stiffness and deformities, heart valve 
problems, but may have a normal lifespan. Intermediate 
phenotypes have accordingly been termed Hurler/Scheie 
syndrome [381]. 
Several studies have been undertaken to correlate the 
biochemical parameters with the clinical phenotype of the 
disease. Although no absolute correlation has been found, 
it seems that most patients with the severe disease have no 
detectable a-L-iduronidase protein, whereas protein as well 
as a-L-iduronidase activity can be detected in fibroblasts 
of most, although not all of Scheie patients [188]. The 
cDNA and the gene of the a-L-iduronidase have been 
cloned [189,190]. Southern blot analysis of more than 40 
patients detected no gross abnormalities of the gene, show- 
ing that deletions are not frequent in MPS I. Several point 
mutations have been described (see Fig. 12). Among Euro- 
pean patients an allele with a premature termination codon 
at position 402 (Trp-402 > ter) accounts for 47% of mutant 
a-L-iduronidase alleles and an allele with a termination 
codon at position 70 (Gin-70 > ter) for 15% [398]. Patients 
homozygous for these premature termination alleles suf- 
fered from the most severe type of disease and, in most 
cases, died before the age of 4 years [191]. In fibroblasts of 
these patients no a-L-iduronidase protein was detected. 
Homozygotes for a Pro-533 > Arg allele and a Trp-402 > 
ter/Pro-533 > Arg genetic ompound showed a somewhat 
milder intermediate course of disease; the latter died at the 
age of 12 years [192]. In fibroblasts of a Trp-402 > 
ter/Pro-533 > Arg heterozygote, low levels of a-L- 
iduronidase protein and activity were detected, and Pro- 
533 > Arg homozygotes seem to be less severely affected 
than genetic compounds for a null allele. Thus, it seems 
that the Pro-533 > Arg allele is associated with a less 
severe form of the Hurler type MPS I. 
A patient suffering from the mild Scheie form of MPS I 
was found to be a genetic compound for the frequent 
Trp-402 > ter allele and an allele that had a splice acceptor 
site mutation in intron 5 [256,266]. Due to this mutation 
most transcripts use a cryptic splice site 28 nucleotides 5' 
of the normal splice site. However, the latter is still used 
with low efficiency, so that low amounts of RNA tran- 
scripts remain correctly spliced. These transcripts are trans- 
lated into low amounts of a-L-iduronidase, which explains 
the mild phenotype of the patient. Thus, this mutation 
resembles the splice acceptor site mutation in exon 11 of 
the /3-subunit of /3-hexosaminidase, which causes a mild 
type of Sandhoff disease [51]. 
The emerging pattern of genotype-phenotype correla- 
tion in MPS I thus resembles that of other lysosomal 
A ^ 
// 
B-0 
I 
15% 
S 
I 
47% 
Fig. 12. Structure of the a-L-iduronidase g ne and mutations causing mucopolysaccharidosis typeI/Hurler and Scheie syndrome. The most frequent 
alleles are indicated by bold lines. Numbers give the frequencies. Mutations associated with mild disease are shown on top. References are in parenthesis 
[191,192,254-256,266,268,398]. 
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storage diseases, such that homozygosity for null alleles 
causes severe disease and alleles associated with some 
residual activity allow for a milder course of the disease. 
Although not yet analysed at the molecular level, one 
mutation is accompanied by a phenomenon that is so far 
unique among lysosomal storage disorders. In fibroblasts 
of a patient suffering from severe type of disease six times 
more a-L-iduronidase protein could be detected than in 
normal fibroblasts [193]. The enzymatically inactive mu- 
tant a-L-iduronidase is sorted normally to the lysosome, 
but its proteolytic processing to the mature enzyme is 
delayed. It is not yet clear, whether the increase in a-L- 
iduronidase protein is due to a prolonged half life of the 
mutant polypeptide or to an enhanced synthesis. The latter 
would suggest a feedback mechanism by which the en- 
zyme or its substrate controls the transcription or transla- 
tion of a-L-iduronidase mRNA. 
4.2. Mucopolysaccharidosis type H/Hunter syndrome 
Mucopolysaccharidosis type II (MPS II) is caused by 
the deficiency of a-L-iduronate-2-sulfate sulfatase. The 
enzyme desulfates iduronate-2-sulfate residues, which can 
be found in heparan and dermatan sulfate. Deficiency of 
the enzyme causes accumulation of degradation i termedi- 
ates [381]. MPS II is the only mucopolysaccharidosis that 
is inherited as an X linked trait. Clinically, it resembles 
MPS I, with skeletal abnormalities, hepatosplenomegaly, 
but less severe mental retardation and no corneal clouding. 
The spectrum of clinical severity is broad, t~-L-iduronate- 
2-sulfate sulfatase cDNA has been cloned and the structure 
of the gene has been determined [194,261,274]. The cDNA 
sequence predicts a protein of 550 amino acids and the 
deduced amino acid sequence shows a strong homology to 
other lysosomal and non lysosomal sulfatases. The gene 
seems to be prone to deletions, which have been detected 
in about every fourth patient [195,196]. Complete deletions 
of the gene can be found in 8% of patients [197], and those 
always suffer from the most severe type of MPS II as do 
patients with other gross rearrangements. Thirty one point 
mutations have been described which cause severe, inter- 
mediate or mild type of disease (see Fig. 13). Most of the 
mutations are private and their effects on the enzyme have 
not yet been studied [293]. No correlation between mutant 
proteins having some residual activity and milder forms of 
disease have been reported. Conclusions about genotype- 
phenotype correlation cannot be drawn yet, but the fact 
that on one hand large deletions are always associated with 
severe form of disease and on the other hand such dele- 
tions have never been found among mildly affected pa- 
tients, would fit into the pattern of genotype phenotype 
correlation seen in other lysosomal storage diseases. MPS 
II provides another example for mutations occurring in the 
same codon, but which lead to different clinical pheno- 
types. An Arg-468 > Trp substitution was in a mildly 
affected patient [338], while the same amino acid was 
changed to glutamine in a patient suffering from severe 
type of disease [258]. 
4.3. Mucopolysaccharidosis type IV / Morquio A syndrome 
Mucopolysaccharidosis type IV (MPS IV)is caused by 
the deficiency of N-acetylgalactosamine-6-sulfate sulfa- 
tase. This enzyme cleaves sulfate residues from sulfated 
galactose found in keratan sulfate or sulfated N-acetyl- 
galactosamine found in chondroitin-6-sulfate [381]. MPS 
IV is characterized by corneal clouding, severe skeletal 
deformities such as dwarfism, odontoid hyperplasia, 
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Fig. 13. Structure of the Ot-L-iduronate-2-sulfate sulfatase and mutations causing mucopolysaccharidosis type II/Hunter syndrome. Mutations causing 
milder phenotypes are shown on top. Deletions have been found in about 20% of patients. Since they have not been exactly defined, they are not shown in 
this figure. References are in parenthesis [197,198,257,258,267,293,294,338]. 
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Fig. 14. Schematic structure of the coding sequence of the arylsulfatase B 
cDNA and mutations causing mucopolysaccharidosis type 
VI/Maroteaux-Lamy syndrome. N and C depict the amino and car- 
boxyterminus, respectively. Since the structure of the gene has not been 
completely resolved, only the exon boundaries and numbers are indicated. 
Mutations causing mild phenotype are shown on top. References are in 
parenthesis [204-207,245,260]. 
kyphosis, hyperlordosis, dysostosis multiplex, but the ab- 
sence of neurologic involvement [381]. A broad spectrum 
of clinical variability has been described. The cDNA [199] 
and the gene [363] have been cloned. The cDNA has 2339 
bp and contains an open reading frame which predicts a 
protein of 522 amino acids [199]. As for ot-L-iduronate-2- 
sulfate sulfatase the deduced amino acid sequence shows 
strong homology to other sulfatases of different function. 
The gene contains 14 exons and is about 50 kb long [363]. 
Two point mutations have been characterized. A deletion 
of two nucleotides causes a frameshift at position 1342 of 
the cDNA and was found in a patient with the severe form 
of the disease. In a patient with the mild form of disease, 
an Asn-204 > Lys substitution has been found. Since this 
amino acid is part of a potential N-glycosylation site the 
mutation leads to the loss of an oligosaccharide side chain 
[2001. 
4.4. Mucopolysaccharidosis type V1/Maroteaux Lamy 
syndrome 
Mucopolysaccharidosis type VI (MPS VI) is caused by 
a deficiency of arylsulfatase B. This enzyme catalyses the 
hydrolysis of the sulfate ester in N-acetylgalactosamine-4- 
sulfate. Due to this deficiency, patients are unable to 
metabolize chondroitin-4-sulfate and dermatan sulfate 
[381]. There is a wide range of clinical severity. Patients 
have no neurologic involvement, but multiple skeletal 
malformations, hepatosplenomegaly, corneal clouding and 
frequently aortic valvular dysfunction [381]. Biochemical 
studies have been performed to correlate the residual en- 
zyme activity with the clinical phenotype of the disease 
[201]. In these studies a trisaccharide substrate resembling 
the oligosaccharides found in dermatansulfate has been 
used. No arylsulfatase B protein or enzyme activity could 
be detected in the majority of cell lines from severely 
affected patients. All mildly affected patients howed some 
enzyme activity and the highest activity of about 5% of 
normal being present in a patient, who is still healthy at the 
age of 45 [201]. 
Cloning of the cDNA revealed high homology to other 
sulfatases [202]. The gene is large and has only partially 
been characterized [203]. A variety of mutations have been 
identified, but none of the mutant alleles is frequent show- 
ing genetic heterogeneity for this disease (see Fig. 14). 
Two mutations have been studied in detail. A Gly-137 > 
Val substitution was found in homozygosity in a patient 
with the intermediate ype of disease [204]. The mutant 
enzyme was catalytically normal, but was highly unstable. 
In another patient with the intermediate form of the disease 
the termination codon was substituted by Gin. The mutant 
protein had a 50 amino acid C terminal extension. Surpris- 
ingly, this mutant enzyme showed a 20 times higher 
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Fig. 15. Structure of the fl-o-glucuronidase g ne and mutations causing mucopolysaccharidosis type VII/Sly syndrome. Designation of mutations are as 
described in Fig. 1 and 2. Mutations associated with hydrops fetalis are shown in bold letters. References are in parenthesis [208,211-213,295]. 
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maximal velocity of substrate turnover, while g m was 
only two times higher. Thus the mutant enzyme is catalyti- 
cally more efficient han the wild type enzyme. The defi- 
ciency of the enzyme activity in the patient could be 
explained by a rapid degradation of the mutant enzyme in 
the ER [205]. 
4.5. Mucopolysaccharidosis type VII~Sly syndrome 
Mucopolysaccharidosis VII (MPS VII) is caused by the 
deficiency of the enzyme fl-D-glucuronidase. This enzyme 
hydrolyses terminal glucuronic acid residues from gly- 
cosaminoglycans dermatan and heparan sulfate, chon- 
droitin-4 and -6 sulfate [381]. The clinical picture shows a 
wide spectrum of severity and resembles that of MPS I and 
MPS II. Patients suffer from skeletal dysplasias, hep- 
atosplenomegaly, and moderate mental retardation. Intelli- 
gence can be normal in late onset cases [381]. In addition a 
severe neonatal from of MPS VII exists, which already 
presents during pregnancy as a hydrops fetalis [208]. The 
cDNA [210] and the /3-D-glucuronidase g ne have been 
cloned [209]. So far, seven mutations have been described 
(see Fig. 15). Homozygosity for an Arg-382 > Cys substi- 
tution was found in an intermediately affected patient [211] 
and homozygosity for Ala-619 > Val in a mildly affected 
individual [212]. Both substituted amino acids are highly 
conserved among glucuronidases of different species 
(mouse, rat, E. coli). Three alleles are associated with 
hydrops fetalis, the most severe form of disease [208,295]. 
The mutations of these alleles cause an Arg-216 > Trp, an 
Ala-354 > Val and an Arg-611 > Trp substitution, respec- 
tively [295]. The effects of two of these substitutions have 
been studied in more detail. The Arg-611 > Trp substitu- 
tion causes a complete loss of enzyme activity. The inac- 
tive enzyme is unstable and fails to form tetramers with 
wild type monomers from other species [208]. When the 
Ala-354 > Val substituted enzyme is expressed in COS 
ceils or in glucuronidase deficient murine fibroblasts a 
surprisingly high residual enzyme activity of 30-40% 
when measured with an artificial substrate was found. 
These findings contrasted with the severe form of disease 
and the low enzyme activity measured in the patients 
fibroblasts. The reason for this discrepancy remains un- 
clear, although it was suggested that even a slight overex- 
pression of the mutant enzyme may drive folding reactions 
in the ER towards a properly folded polypeptide and that 
this reaction may not occur in the patients fibroblasts 
where the amount of enzyme expressed is much lower 
[208]. 
A similar phenomenon was also observed for a Trp-627 
> Cys substituted /3-D-glucuronidase, for which it could 
be proven experimentally that the level of residual enzyme 
activity in transfection experiments correlates with the 
degree of overexpression [213]. These findings are not 
unique for /3-D-glucuronidase, but have also been de- 
scribed for /3-hexosaminidase A [389]. Although the dis- 
ease is rare, it has attracted considerable attention since it 
was the first lysosomal storage disease for which a sponta- 
neous mouse model existed and the cDNA of the defective 
gene was available. Thus, several therapeutic trials involv- 
ing gene transfer have been performed in this model of 
lysosomal storage disease, the results of which will be 
discussed in the section on therapy of lysosomal storage 
diseases. 
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Fig. 16. Structure ofthe ot-o-glucosidase gene and mutations causing Pompe disease. Mutations causing adult ype of glycogenosis type II are shown on 
top. //indicates that he size of the intron is unknown. References are in parenthesis [216,217,219,220,259,399]. 
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4.6. Glycogen storage diseases / Pompe disease 
Pompe disease is the only lysosomal disease among the 
glycogen storage disorders and results from the deficiency 
of OZ-D-glucosidase, which hydrolyses a-l,4 and a-l,6 
glycosidic linkages. Deficiency of the enzyme results in 
intralysosomal storage of glycogen in nearly all tissues, but 
symptoms are mainly due to functional impairment of 
skeletal and heart muscle and the nervous system [382]. 
The severe infantile form starts in the first months life with 
muscle weakness, macroglossia, hepatomegaly and car- 
diomyopathy [382]. Death ensues before the second year of 
life. Adult forms of Pompe disease are mild and symptoms 
may be confined to skeletal muscle weakness. Between 
these extremes, there is a spectrum of intermediate forms 
of disease [382]. The cDNA and the gene of a-o-gluco- 
sidase have been cloned [214,215]. The amino acid se- 
quence deduced from the cDNA revealed strong homology 
to non lysosomal enzymes isomaltase, maltase and sucrase 
[214]. The phenotypic variation in Pompe disease is most 
likely explained by different levels of residual enzyme 
activity. Such correlation was already apparent before 
mutations in the a-D-glucosidase g ne were analysed [241]. 
Eight mutant alleles have been characterized. A deletion of 
exon 18 and the adjacent intronic sequences seems to be 
the most frequent mutation among Dutch patients and has 
been found in the heteroallelic form in severely and mildly 
affected patients (see Fig. 16). A Met-318 > Thr substitu- 
tion, which creates an additional N-glycosylation site [216] 
and a Glu-521 > Lys substitution, which is located in the 
neighbourhood of the catalytic site at position Asp-518 
have been found in patients uffering from the infantile 
form of disease [217,218]. Both amino acid residues are 
conserved among the homologous enzymes mentioned be- 
fore. 
So far two patients with the adult form of Pompe 
disease have been examined and both were genetic com- 
pounds for two defective O~-D-glucosidase alleles. In one 
allele, an Arg-854 > ter substitution was identified and 
biochemical studies revealed that no protein is expressed 
from this allele [220]. Three amino acid substitutions were 
found in the other allele, an Asp-645 > Glu, a Val-816 > 
lie, and a Thr-927 > Ile substitution [219,220]. Two, Val- 
816 > lie and Thr-927 > lie, are polymorphisms. The lat- 
ter abolishes a glycosylation site, but does not affect the 
function of the enzyme [220]. Asp-645 > Glu has been 
identified as the deficiency causing mutation [220]. Trans- 
fection studies revealed that no enzymatic activity mea- 
sured with the natural substrate can be expressed from a 
cDNA encoding this mutant enzyme [220]. The second late 
onset patient had a Gly-643 > Arg substitution on one 
allele and a Arg-725 > Trp on the other [259]. Studies in 
the biosynthesis of a-D-glucosidase ubstituted with these 
amino acids showed that in cultured cells both mutant 
polypeptides are retained and degraded in the ER [220,259]. 
Although genetically different, both adult patients have 
one common feature. In both patients a discrepancy was 
noted between the very low enzyme activity found in 
cultured fibroblasts, cultured muscle cells and in transfec- 
tion studies and the mild phenotype of the patient 
[219,220,259]. This may be explained by differences in the 
expression of the defect under different conditions. When 
cultured fibroblasts of this patient were examined electron- 
microscopically, a D-glucodiase was detected in the dilated 
ER. This was also found in a biopsy of muscle fibers, but 
in addition in muscle tissue it appeared that fully matured 
intralysosomal enzyme was more abundant han in the 
cultured cells [264]. The apparent discrepancy of residual 
activity and phenotype may be due to differences in the 
processing of the mutant enzyme under different condi- 
tions, such that it is largely degraded in the ER in cultured 
cells whereas some enzyme reach the lysosome in vivo 
[264]. 
4. 7. Pathogenesis of lysosomal storage diseases 
The analysis of disease causing mutations is important 
for the understanding of a disease but tells little about the 
pathogenesis. In some lysosomal storage diseases, part of 
the symptoms can simply be explained by the macromolec- 
ular effects of storage material. In Maroteaux-Lamy s n- 
drome, storage of dermatan and chondroitin sulfate in the 
heart valves causes valvular insufficiency and stenosis due 
to thickening of the endothelial walls, which leads to 
cardial insufficiencies in the patients. On the other hand, 
symptoms may be a consequence of effects that the storage 
material exerts on the metabolism of a single cell. These 
may simply be due to mechanical effects of massively 
enlarged lysosomes, which may rather unspecifically per- 
turb various intracellular functions. However, there are 
several examples which demonstrate that more specific 
effects of the storage material itself may explain the 
pathogenesis more adequately. In several sphingolipidosis, 
e.g., metachromatic leukodystrophy [221], Krabbe disease 
[222], GM2 gangliosidosis [223] and Gaucher disease [224] 
an abnormal accumulation of lysosphingolipids has been 
demonstrated. Lysosphingolipids represent deacylated 
forms of sphingolipids in which the acyl residue bound to 
the N of the sphingosine is missing. Lysosphingolipids 
have been shown to be lytic and to be potent inhibitors of 
protein kinase C [225]. In brains of metachromatic 
leukodystrophy patients, 50 to 100 times more lysosul- 
fatide has been detected and it is conceivable that via 
inhibition of protein kinase C, this compound interferes 
with a variety of cellular functions [221]. In the brain of 
twitcher mice, which are a model for human Krabbe 
disease, the accumulation of lysogalactocerebroside (psy- 
chosine) has been demonstrated. When dorsal root gan- 
glion cells from these mice were cultured in vitro they 
grew poorly and died. Compared to normal cells 70 times 
more psychosine was found in affected cells [226]. 
Already many years ago, it has been noted that pyrami- 
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dal neurons in GM2 gangliosidoses develop large neuronal 
processes, which have been termed meganeurites [227]. 
Although all cells store GM2 ganglioside only the pyrami- 
dal neurons develop meganeurites. In addition the axonal 
hillock of pyramidal cells gives rise to spiny ectopic 
dendrites, which are able to form ectopic synapses [227]. It 
is obvious, that such ectopic connections interfere with 
information processing in a neuronal network and may 
explain, in part, the neurological symptoms of the patients. 
The storage of GM2 ganglioside is not restricted to GMZ 
gangliosidosis but, for reasons that are not understood, 
occurs to a lesser extent also in c~-mannosidosis [364,365]. 
In a feline model of this disease, only a few pyramidal 
neurons present ectopic neurites. It was recently demon- 
strated that only those cells that store GM2 ganglioside 
develop additional neurites and that the storage of GM2 
ganglioside precedes the development of abnormal den- 
drites [228]. Gangliosides have been implicated in a variety 
of cellular functions. They can act as receptors, or ligands 
[366] and may play key roles in differentiation, since their 
pattern of expression shows characteristic changes during 
embryonic development [367]. If one speculates that GM2 
ganglioside may play a physiological role in neurite forma- 
tion of pyramidal cells, its pathologic accumulation i  GM2 
gangliosidosis or c~-mannosidosis may continuously trigger 
parts of developmental processes resulting in the de novo 
formation of additional, ectopic dendrites. 
Caprine /3-mannosidosis an example where the 
amount of accumulated storage material does not correlate 
with the severity of the lesions. The main symptom of 
these animals is a myelin deficiency, which is severe in 
cerebral hemispheres, but only moderate in the spinal cord 
[275]. When the amount of storage material was deter- 
mined, there was no correlation of oligosaccharide accu- 
mulation and demyelination a d it even seemed that more 
storage material was present in the less severely affected 
spinal cord [400]. When oligodendrocytes of affected ani- 
mals were cultured an increased number of immature glial 
progenitor cells were found, suggesting a defect in oligo- 
dendrocyte differentiation [230]. 
In Gaucher disease the actual amount of glucocerebro- 
side in liver tissue is in between 0.1 and 18 mg per gram 
of liver tissue [269,270]. For this reason, the hepatomegaly 
cannot simply be explained by the accumulation of gluco- 
cerebroside. Pathologic examinations revealed, that an in- 
crease in cell number explains the organomegaly in this 
disease [368]. It has been shown, that macrophages can be 
stimulated in vitro to secrete cytokines in a dose-dependent 
response upon addition of glucocerebroside [271]. These 
cytokines may be secreted by macrophages in Gaucher 
disease and may stimulate other cells to divide. 
This summary of pathophysiologic correlates of various 
lysosomal storage diseases may seem like a random collec- 
tion of phenomenology with questionable relevance for 
pathogenetic mechanisms. They indicate, however, that 
there may a lot more to learn from lysosomal storage 
diseases. The elucidation of the pathogenesis of lysosomal 
storage diseases is greatly facilitated by the availability of 
animal models. For various diseases naturally occurring 
models exist for example in dogs [370], cats [369], or rats 
[384]. Spontaneous murine models have been described for 
mucopolysaccharidosis type VII [404], for Krabbe disease 
[383], and for Niemann Pick type C [342]. 
Recently, the generation of a mouse model by homolo- 
gous recombination f the /3-D-glucocerebrosidase locus in 
embryonic stem cells was reported [132]. Homozygous 
mutant mice were already severely affected at birth and 
died within the first day of life. They showed hyperkera- 
totic skin, were cyanotic and did not move and feed as 
their normal littermates. Examination of the animals re- 
vealed a storage of glucocerebroside in macrophages of
several organs. However, the storage was not extensive 
enough to explain the rapid death of the mice. Thus, it has 
been speculated that the accumulation of toxic compounds 
may be responsible for the severe phenotype of affected 
animals. The skin in these mice was found to be hyperker- 
atotic. This symptom in mice resembled that found in 
humans with neonatal form of Gaucher disease, which due 
to their ichthyotic appearance of the skin have been termed 
collodion babies [265]. 
4.8. Therapy of lysosomal storage disease 
The first lysosomal storage disorder for which treatment 
was available has so far not been discussed in this review, 
since the protein which is defective has not yet been 
purified. This disease is cystinosis. It is caused by the 
deficiency of a lysosomal cystine transporter, which trans- 
ports cystine that has been liberated in the process of 
lysosomal protein degradation back into the cytosol (see 
Pisoni et al. [79]). Due to the deficiency of this transporter 
cystine accumulates in the lysosomes. Since cystine is 
poorly soluble, crystals form easily in the tissues. The 
main symptom is a nephropathy causing renal failure. 
Cysteamine is a weak base, which enters the lysosome, 
reacts with cystine to form a disulfide linked cystine 
cysteamine compound. This compound can exit the lyso- 
some via a transport system for cationic amino acids, 
which is not affected in cystinosis. Therefore renal func- 
tion in the patients can be preserved by the oral application 
of cysteamine [272]. 
Gaucher disease type I is the first lysosomal storage 
disorder that has been treated successfully by enzyme 
replacement [233]. Compared to other lysosomal storage 
diseases, the prerequisites for enzyme replacement have 
been particularly favourable in type I Gaucher disease. 
Accumulation of the lipid in this disease is restricted to 
macrophages [348]. These cells express mannose receptors, 
which can endocytose polypeptides bearing terminal man- 
nose residues on their oligosaccharide side chains and 
deliver them to lysosomes [372]. /3-D-glucocerebrosidase 
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can be modified enzymatically to increase the number of 
terminal mannose residues on oligosaccharide side chains 
and the modified enzyme is targeted 40-70 times more 
efficiently to macrophages than the unmodified enzyme 
[403]. fl-D-glucocerebrosidase purified from human pla- 
centa has been used in a number of patients with the 
nonneuronopathic form of Gaucher disease. Enzyme re- 
placement increases hemoglobin and platelet counts and 
leads to a regression of hepatosplenomegaly within 6 to 12 
months of treatment [232,233]. Gaucher patients frequently 
suffer from skeletal abnormalities and it seems that after 
the start of enzyme replacement, no new skeletal abnor- 
malities will develop and bone abnormalities may also be 
reversed [373]. The idea that lysosomal storage disease 
may be cured by enzyme replacement therapy was fueled 
by the observation that in cultured cells of patients torage 
material could be degraded when the missing enzyme was 
exogenously supplied in the culture medium [374]. At that 
time, enzymes were not available in amounts ufficient for 
continuous enzyme replacement in clinical trials. Recombi- 
nant DNA technology nowadays allows to produce lysoso- 
mal enzymes in amounts that will make clinical trials for 
various lysosomal storage diseases feasible in the near 
future. Since it can be expected that exogenously supplied 
enzyme does not penetrate the blood brain barrier, suitable 
candidates for enzyme replacement are disorders without 
neurological involvement (e.g., Maroteaux Lamy, Morquio 
B, Fabry, late onset Pompe disease). However, leaving 
economical consideration aside, those disease where extra- 
neural complication is major source of discomfort, pain or 
death, should not be exempted. This may for example be 
MPS I, in which respiratory infections, ear infections and 
obstructive airway disease are common complications [381] 
or MPS IV, in which subluxation of the odontoid process 
[381] is a frequent lethal complication. 
The prime candidates for enzyme replacement are pa- 
tients with adult Pompe disease and with the cardiac 
variant of Fabry disease. In these disorders the target cells 
are muscle cells, heart muscle cells and endothelial cells, 
which are readily accessible by the blood stream. In mu- 
copolysaccharidoses it may be more difficult to provide 
some cells with sufficient enzyme due to poor vasculariza- 
tion of some target tissues. Thus, hepatosplenomegaly is 
likely to be treatable, but skeletal abnormalities may be 
more difficult to influence. Enzyme replacement has been 
tried with recombinant /3-D-glucuronidase in newborn MPS 
VII mice [375]. The distribution of the injected enzyme 
resembled the pattern of expression of the mannose-6- 
phosphate receptors [376] through which lysosomal en- 
zymes are endocytosed. Most of the substituted enzyme 
was found in liver and heart, but significant amounts were 
also found in brain. Closer examination revealed that the 
brain enzyme is mainly found in blood vessel and meninges 
but not in neurons [375]. To what extent he pathology and 
symptoms of the infused animals will be altered has not 
yet been examined. 
The potential use of bone marrow transplantation has 
been documented in several animal models of lysosomal 
storage disease [238-240]. Since bone marrow derived 
macrophages are able to cross the blood brain barrier and 
reside as microglial cells in the brain, they may turn out to 
be a useful vector for enzyme delivery into the brain [390] 
and therefore bone marrow transplantation is more likely 
to influence neural pathology than enzyme replacement. 
Improvement of neurologic symptoms and partial reversal 
of neural lesions after bone marrow transplantation has 
been seen in several animal models of lysosomal storage 
disease [167,168,239]. In twitcher mice, this has led to an 
extended life span, but failed to cure the animals, indicat- 
ing that the defect was only partially complemented [238]. 
In the fucosidosis dog, too, improvements of neurologic 
symptoms were found [240]. In both animal models in- 
creased enzyme activities were found in the brain. In the 
fucosidosis dog, the increased enzyme activities in the 
brain were not detectable before 6 months after transplan- 
tation, indicating that bone marrow derived macrophages 
infiltrated the brain only slowly. This may explain why the 
results of bone marrow transplantation were better when 
animals were transplanted before the development of 
symptoms [240]. 
A dramatic improvement of neurologic symptoms and 
neural pathology has been found in bone marrow trans- 
planted cats, suffering from a-mannosidosis. Treated ani- 
mals showed little neurologic symptoms up to 2 years after 
transplantation, while untreated animals deceased after 
about 6 months of age [169]. Histologically lysosomal 
storage in neurons was prevented and also reversed. 
Whether the differences in the effectiveness of bone mar- 
row transplantation i diseases with involvement of the 
nervous ystem are due to disease or species related factors 
is not yet clear. 
In humans, bone marrow transplantation has been tried 
for various lysosomal storage disorders (for review see 
[401]). Reversal of visceral pathology has been demon- 
strated in several diseases. In bone marrow transplanted 
MPS VI patients for instance hepatosplenomegaly de- 
creased within 2 years after transplantation [402]. Improve- 
ments of neurological symptoms have been documented in
several cases [391,392], however, the benefits remain con- 
troversial. Although in some cases, the course of the 
disease after bone marrow transplantation has been com- 
pared to that of affected untreated siblings, it cannot be 
excluded that at least parts of the effects that were seen are 
due to intrafamilial phenotypic variations rather than bone 
marrow transplantation. Since it has so far only been 
possible to follow patients for some years it remains to be 
seen whether the effects of the therapy are satisfying or 
whether a severe disease has just been converted into a 
milder but still lethal form. More clinical studies are 
necessary for evaluation of the therapy. 
The combination of gene transfer techniques into 
hematopoietic stem cells and autologous bone marrow 
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transplantation will lead to novel approaches for the treat- 
ment of lysosomal storage diseases in the near future. 
Autologous bone marrow transplantation with retrovi- 
rally modified cells has been performed in /3-D-glucuroni- 
dase deficient mice [242]. Mice expressing different levels 
of /3-o-glucuronidase from the inserted retrovirus have 
been obtained. When compared to normal animals up to 
2%, 6%, and 26% of enzyme activity was found in liver, 
spleen and bone marrow of transplanted mice, respec- 
tively. There seemed to be a correlation between the 
amount of enzyme xpressed in individual animals and the 
reduction of storage material, such that high expressers had 
a more complete reversal of organ pathology. However, in 
none of the mice was the /3-D-glucuronidase able to correct 
the skeletal and neuronal abnormalities and no increase in 
enzyme activity in the central nervous ystem was found. 
With the same animal model a different approach was 
taken by Moullier et al. [262]. Fibroblasts were removed 
from mutant mice and were infected with a fl-D-glucuroni- 
dase cDNA containing retrovirus. These /3-D-glucuroni- 
dase expressing fibroblasts were then imbedded into a 
collagen lattice on plastic fibres. When cells had grown to 
high density on this support, it was transplanted into the 
peritoneal cavity of the mutant animals. These lattices 
were rapidly vascularized and have been termed neoor- 
gans. These neoorgans were kept in the peritoneal cavity 
for up to 155 days. No uncontrolled growth, fibrosis or 
immunological reaction was observed. When compared to 
control animals the transplanted animals showed increased 
enzyme activities in spleen, liver, lung and other organs. 
The enzyme activity varied between 0.5% and 6% of 
normal ittermates. The therapeutic effect was mainly seen 
in liver and spleen, which showed a drastic reduction of 
storage material. No effect was seen on the bone and brain 
lesions and this approach may therefore be more suitable 
for nonneuronopathic d seases. 
To achieve an adequate therapy for diseases with neuro- 
logical symptoms, the development of vectors which di- 
rectly target neurons or glial cells has to be considered. 
Two have attracted particular attention, namely the herpes 
simplex virus and adenovirus derived vectors. In /3-o- 
glucuronidase-deficient mice, transient in vivo expression 
in a limited number of neurons has been achieved with 
herpes simplex-derived vectors [243]. However, the com- 
plexity of the herpes virus genome, its tendency to recom- 
bine and the fact that herpes simplex encephalitis is a 
life-threatening disease, make it unlikely that this vector 
will be used in clinical trials in the foreseeable future. 
5. Concluding remarks 
Work on lysosomal storage diseases during the last 
years has focused on the cloning of genes and the analysis 
of mutations. The results of these efforts have shed some 
light on genotype-phenotype correlations in lysosomal 
storage diseases. Three facts became apparent: First, in 
most lysosomal storage disorders the residual enzyme ac- 
tivity is an important determinant of clinical severity. 
Second, low residual enzyme activities are sufficient o 
sustain a normal phenotype and, third, among patients with 
identical genotype the clinical variability is still remark- 
able. Other genetic or epigenetic factors have to be postu- 
lated and only their identification will allow a complete 
understanding of phenotypic variability. The expectation 
that the elucidation of phenotypic variability at the molecu- 
lar level would allow for precise prediction of the clinical 
course has not been met. In many cases, molecular analy- 
sis yielded little practical consequences, because frequently 
the phenotypic variation occurring on the same genotype 
makes a prediction of the outcome of the disease on an 
individual basis impossible. Furthermore, we have learned 
that apparently small differences in the mutant enzyme can 
cause different clinical phenotypes. The same codon can 
be affected by mutations causing different amino acid 
substitutions. Although in some instances the effects of 
two mutations on the enzyme seemed to be identical when 
analysed in heterologous cells, either mutation cause dif- 
ferent clinical phenotypes (e.g., Tay Sachs disease and 
MPS II). Furthermore, the expression of the defect may be 
tissue-specific or differ in vivo and in vitro. In metachro- 
matic leukodystrophy and Pompe disease the clinical phe- 
notype did not correlate with the residual enzyme activity 
found in fibroblasts of some patients. Our current knowl- 
edge is yet incomplete and our in vitro methods are too 
crude to understand the complexity of factors that influ- 
ence the patients phenotype. 
Knowledge of mutations has only improved the genetic 
counselling for diseases which occur at high frequency in a 
particular ethnic group and where only few alleles account 
for the majority of all mutant alleles (e.g., Tay Sachs or 
Gaucher disease in the Ashkenazi Jews). This has made 
population based screening for particular alleles feasible. 
In contrast, in most storage diseases heterogeneity of mu- 
tant alleles has made the diagnosis based on the detection 
of mutations unpractical. Simple functional tests like en- 
zyme activity determinations and analysis of metabolites in
urine are still the first step in establishing the diagnosis. 
With particular importance for genetic counselling im- 
provements due the knowledge of specific mutations have 
been seen with the genetic differentiation of pseudodefi- 
ciencies like in Tay Sachs disease and metachromatic 
leukodystrophy. 
Aside from the genotype-phenotype correlations and 
some improvements of diagnostic tests, the analysis of 
mutations was expected to reveal aspects of the biological 
function of lysosomal enzymes. Unfortunately, most of the 
amino acid substitutions have not been examined with 
respect to their influence on the particular enzyme. In 
cases where this has been done, the mutations frequently 
do not interfere with specific functions of the enzymes. A
notable exception is the a-subunit of /3-hexosaminidase A 
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where several mutations affecting the substrate specificity 
in different ways cluster in a particular egion of the 
enzyme. The mutations occurring in the saposin genes 
have allowed to conclude which saposin is involved in the 
degradation of a particular lipid in vivo. Most of the 
mutations cause rather unspecific effects like ER retention 
and rapid degradation and have not contributed to the 
understanding of specific biological functions of poly- 
peptides. Research on lysosomal storage diseases is now 
focussing on the development of transgenic mouse models. 
These are expected to facilitate studies on the molecular 
mechanism of pathogenesis and in particular trials on the 
suitability of gene replacement therapies. 
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